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ABSTRACT 
 
Background:  
Coronary artery disease is set to be the world’s leading cause of mortality by 2020. Hence novel 
treatment strategies are urgently required to protect the human myocardium against ischemia-
reperfusion injury. This thesis examines the role of the mitochondrial permeability transition pore 
(MPTP) as a novel target for myocardial protection by interventions applied solely at the time of 
reperfusion, which can protect the human heart against lethal reperfusion injury.  
 
Methods and Results:  
Using human atrial tissue (harvested at the time of routine cardiac bypass surgery), subjected to 
simulated ischemia and reperfusion injury model, we have demonstrated that the opening of the 
MPTP at the time of reperfusion is a critical determinant of cardiomyocyte death. We also show 
that inhibiting MPTP opening, by administering known pharmacological inhibitors of MPTP at 
the onset of reperfusion, is cardio-protective. Using experimental models in adult human atrial 
trabeculae, we demonstrate that inhibiting MPTP opening at the time of reperfusion improves 
myocardial contractile function. Also using human atrial cardiomyocytes we demonstrate that 
inhibiting MPTP opening at the time of reperfusion improves cellular viability. Finally using the 
human atrial cardiomyocyte model for inducing and detecting the MPTP opening, we 
demonstrate the opening of MPTP and also the inhibitory effect of known MPTP inhibitors on 
MPTP opening. 
 
Conclusion:  
We find that MPTP opening does occur in the human atrial cardiomyocyte following ischemia-
reperfusion injury, and that inhibiting the opening of the MPTP at the time of reperfusion, 
provides a potential target for human myocardial protection, when the intervention is applied at 
the time of reperfusion. Therefore, interventions, which target and inhibit MPTP opening, at the 
time of reperfusion, can protect the myocardium from lethal reperfusion injury and may improve 
morbidity and mortality from coronary artery disease. This is useful in the clinical settings of 
ischemia-reperfusion injury such as thrombolysis following an acute myocardial infarction, heart 
surgery and percutaneous transluminal coronary angioplasty. 
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1.1 Coronary Artery Disease 
 
Coronary artery disease (CAD) is the leading cause of death in the world. About 3.8 million 
men and 3.4 million women die of this disease every year
1
. The global burden, in terms of 
disability-adjusted life years (DALY) or “healthy years of life lost” is projected to rise from 
around 47 million DALY globally in 1990 to 82 million DALY in 2020. CAD ranges from sub-
clinical coronary artery disease, angina on exertion, unstable angina and myocardial 
infarction, congestive cardiac failure and finally death.  
CAD is caused by the build up of atherosclerotic plaques in the coronary arteries, 
known as atherosclerosis. This leads to limitation of the coronary blood flow to the 
myocardium resulting in oxygen and nutrient deprivation, termed ischemia. The unstable 
atheromatous plaque can rupture resulting in the formation of a thrombo-embolic plug 
occluding the major coronary arteries. This acute occlusion leads to acute myocardial 
infarction. Salvaging the myocardium in this situation of acute myocardial infarction is by the 
timely restoration of coronary blood flow to the ischemic myocardium by - thrombolysis, 
primary percutaneous coronary artery intervention or coronary artery bypass graft (CABG) 
surgery. Data from the British Heart Foundation (BHF) indicates that CAD in the UK is the 
most common cause of mortality and accounts for more than 125,000 deaths per year. 
Thankfully, the majority of these are non-fatal at the time of presentation. A large proportion of 
patients presenting with CAD benefit from revascularisation either using percutaneous 
coronary intervention or CABG surgery.  
 To salvage viable myocardium following an acute coronary artery occlusion, 
reperfusion is mandatory. However, the restoration of blood flow paradoxically leads to the 
death of cardiomyocytes which were viable just before the ischemic episode. This myocardial 
injury is termed lethal ‘reperfusion injury’
2
 and which in itself can induce cardiomyocyte death 
and increase infarct size. This could possibly explain the increase in the incidence of death 
after an acute myocardial infarction reaching 10% and the incidence of cardiac failure after an 
acute myocardial infarction reaching up to 25% despite optimal management. 
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Therefore myocardial protection against this lethal reperfusion injury is required and 
novel treatment strategies that can be applied after the onset of ischemia but at the time of 
onset of reperfusion need to be identified. 
 One of the most powerful mechanisms for protecting the myocardium before the 
acute coronary artery occlusion / ischemia is to ischemically precondition (IPC) the 
myocardium. This powerful phenomenon was first described in the seminal study by Murry 
and colleagues in 1986
3
. IPC refers to the ability of short periods of ischemia to make the 
myocardium more resistant to a subsequent lethal ischemic insult.  
Cardioprotection has been shown to be achieved by applying the brief episodes of 
non-lethal ischemia and reperfusion to an organ or tissue remote from the heart. This 
phenomenon has been termed remote ischemic ‘conditioning’
4,5
. Remote ischemic 
conditioning can offer widespread systemic protection to other organs which are susceptible 
to acute ischemia–reperfusion injury such as the brain, liver, intestine or kidney. Ischemic 
myocardial injury can also be reduced by another mechanism called ischemic post 
conditioning, which is achieved by interrupting myocardial reperfusion
6
.  
  Although the above mentioned protective strategies are separated by timing of the 
intervention and the conceived mechanisms of action, all these cardio-protective strategies, 
may converge on the mitochondrial permeability transition pore (MPTP) which is the main 
subject of this thesis. This was first described in the late 1970’s by the pioneering studies by 
Haworth and Hunter
7
.   
The aim of this thesis is to explore the critical role of MPTP in ischemia-reperfusion 
injury and examine its relation and contribution in the salvation of the human myocardial 
viability and function.        
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1.2 Myocardial Ischemia-Reperfusion Injury 
 
Myocardial reperfusion injury was first postulated by Jennings et al in 1960
8
. In their 
histological description of reperfused ischemic canine myocardium, they reported cell 
swelling, contracture of myofibrils, disruption of the sarcolemma, and the appearance of intra-
mitochondrial calcium phosphate particles. Reperfusion injury to the heart causes four 
recognised types of cardiac dysfunction i.e. reperfusion induced arrhythmias; myocardial 
stunning; reversible microvascular obstruction; and cell death
9
. 
The concept of lethal reperfusion injury as an independent mediator of cardiomyocyte 
death distinct from ischemic injury is debatable. Some suggest that reperfusion only 
exacerbates the cellular injury that was sustained during the ischemic period
9
. To show the 
existence of lethal reperfusion injury as a distinct mediator of cardiomyocyte death, it is 
important to show that the size of a myocardial infarct can be reduced by an intervention used 
at the beginning of myocardial reperfusion
10
.  
The main causes of reperfusion injury are increased intracellular calcium and reactive 
oxygen species (ROS) which is initiated during ischemia and amplified during reperfusion and 
targeting the mitochondria
11-13
. 
 
1.3 Myocardial Protection by Ischemic Preconditioning  
 
In 1986 Murry et al made a seminal discovery of an endogenous mechanism offering 
profound protection which they termed ischemic preconditioning
14
. In their seminal paper they 
showed that four cycles of 5 minutes of ischemia with intermittent reperfusion were shown to 
limit infarct size by 75%. This cardio-protection is termed as classical or early preconditioning. 
 IPC has been demonstrated in all animal species studied to date including chicken, 
dog, mouse, pig, rabbit, rat, and sheep. The preconditioned state is very transient and lasts 
for only 1-2 hours in anesthetized animals
14,15
 and is lost between 2-4 hours in conscious 
rabbits. Although the initial protection is transient a delayed protection reappears within 24 
hours of the preconditioning stimulus and is termed second window of protection (SWOP)
16
. 
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The original end point used as the assessment for protection from the IPC was infarct 
size and this was expressed as a percentage of the risk zone
3
. Though stunning has been 
used as an end point of assessment, doubts do exist regarding IPC effect on stunning. Post-
ischemic recovery of contractile function is a commonly used end point for IPC
17,18
. IPC has 
been reported to alter the incidence of reperfusion induced arrhythmias in dogs and rats.   
 
1.4 Preconditioning the Human Myocardium 
 
Human ventricular cardiomyocytes and atrial trabeculae studies have been ingeniously used 
as a surrogate to study the effects of ischemic preconditioning. The evidence is reviewed 
below 
 
1.4.1 In Vitro studies 
Ikonomidis et al, were the first to demonstrate the effect of preconditioning in human 
ventricular cardiomyocytes in cell culture and they used trypan blue exclusion and metabolic 
end points of injury
19
. Arstall et al, showed that in addition to classical preconditioning, human 
ventricular cardiomyocytes exhibited delayed cardioprotection 24 hours after a short period of 
simulated ischemia
20
.  
Our group were the first to investigate the preconditioning phenomenon in the human 
atrial muscle obtained from the patients undergoing coronary artery bypass surgery
18
. They 
were able to precondition the human muscle and used post-ischemic recovery of mechanical 
function as the end point.  This has been confirmed by other authors
21
. Ghosh et al, using 
sections from the right atrium, have demonstrated both early and delayed preconditioning 
using both simulated ischemia as well as pharmacological means and used leakage of 
creatine kinase as the index of injury
22
.  
 
1.4.2 In Vivo studies 
Exercise induced angina 
Some patients are able to exercise to the point of angina, take rest and continue further with 
no more symptoms and this phenomenon is termed as warm-up or first effort angina
16
. The 
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above phenomenon was initially thought to be mediated by the coronary vasodilatation and 
recruitment of collateral vessels but some investigations suggests other mechanisms might 
be involved. Okazaki et al and Williams et al, reported a reduction in the severity of angina 
and the degree of S-T segment depression during the second period of myocardial ischemia 
and these changes were not accompanied by the recruitment of collateral vessels and this 
was evidenced by the similar coronary and great cardiac vein blood flow measurements
23
. 
Stewart et al and Tomai et al, showed that the duration of the warm-up angina is 1-2 hours 
after the first period of exercise, a time course that closely parallels classical ischemic 
preconditioning
24,25
. However studies examining the cellular mechanism have given conflicting 
results
26,27
.  
 
Pre-infarction Angina 
Kloner et al, in their retrospective analysis of the TIMI-4 trial, showed that the presence of pre-
infarct angina was associated with smaller infarct size and showed lower creatine kinase 
release, improved left ventricular function with reduced incidence of congestive heart failure 
and shock and reduced mortality
28
. Patients experiencing angina before acute myocardial 
infarction (MI) seem to have reduced occurrence of life-threatening arrhythmias
29
 and a lower 
mortality
30,31
. Reports from TIMI-9B investigators
31
 and studies by Ishihara et al
30
 and 
Yamagishi et al
32
 indicate that angina is only effective if it occurs within 24-72 hours of MI.  
 
Angioplasty studies 
Studies have shown that when the first balloon inflation of the coronary artery is between 60-
90 seconds, indicators of myocardial ischemia such as chest pain severity, ventricular 
regional wall motion abnormality, S-T segment elevation, Q-T depression, ventricular ectopic 
activity, lactate production and release of markers such as Creatinine Kinase  MB (CKMB) are 
attenuated during subsequent balloon inflations and thus providing evidence for myocardial 
adaptation induced by the first period of inflation
33-35
.  
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Surgical studies 
Yellon et al were the first to report that, inducing global ischemia by intermittently cross-
clamping the aorta and pacing the heart (2x3 minutes cycle) followed by 2 minutes of 
reperfusion before a 10 minute period of global ischemia and ventricular fibrillation, ATP 
levels were better preserved (ventricular biopsy – ATP content) during the subsequent global 
ischemia period
36
. Myocardial necrosis was also used as end point where serum levels of 
troponin-T were studied and Jenkins et al showed that patients subjected to the 
preconditioning protocol suffered significantly less myocardial necrosis
37
. Illes et al showed 
that preconditioning the human heart just before the cardioplegic arrest resulted in a 
significant improvement in postoperative cardiac index and reduced inotropic requirement
38
. 
Isoflurane has been shown to have beneficial effects during coronary artery bypass surgery 
by Tomai et al
39
 and also shown to act as a direct preconditioning stimulus
40
.  
 
1.5 Myocardial Protection by Intervening at Reperfusion 
 
Re-establishing coronary blood flow to the ischemic myocardium, following an acute 
myocardial infarction, can itself result in cardiomyocyte death, a phenomenon termed lethal 
reperfusion injury
3
. 
The existence of lethal reperfusion injury as an entity separate from ischemic injury is 
controversial and some commentators have suggested that reperfusion only exacerbates the 
cellular injury sustained during the ischemic period
9
. Reperfusion following a fixed period of 
ischemia can exacerbate the necrotic component of cell death as evidenced by an extension 
in infarct size as shown by some authors
41
.  
 
1.5.1 Protecting the Human Myocardium Against Ischemia-Reperfusion Injury 
 
Glucose-insulin-potassium (GIK) offers cardio-protection in response to ischemia-reperfusion 
injury and was first introduced in 1962 by Sodi-Pallares and colleagues
42
. In the late 1990’s, 
the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) clinical 
trial demonstrating a 29% significant reduction in mortality
43
; as well as the ECLA (Estudios 
Selvaraj Shanmuganathan Chapter 1: Introduction 
23 
Cardiológicos Latinoamérica) clinical trial which reported a 66% reduction in mortality in 
diabetic patients reperfused following an acute myocardial infarction
44
. GIK therapy has also 
been shown to be cardio-protective in the setting of coronary artery bypass graft surgery
45
. 
Clinical studies with magnesium therapy have produce mixed results with the Second 
Leicester Intravenous Magnesium Intervention Trial (LIMIT-2) trial
46
 reporting a benefit but the 
larger fourth International Study of Infarct Survival (ISIS-IV) trial
47
 reporting no benefit.  
The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) demonstrated that 
the administration of adenosine as an adjunct to thrombolysis resulted in a 67% relative 
reduction in infarct size in patients with anterior myocardial infarction
48
.  
 Na
+
-H
+
 exchanger as an adjunct to primary PTCA in patients with an acute 
myocardial infarction reported positively attenuating CKMB release, improved ejection fraction 
and improved regional left ventricular wall motion
49
. Subsequent larger study, ESCAMI trial, 
however reported no attenuation in CKMB release in patients given the Na
+
-H
+
 exchanger 
inhibitor, eniporide as an adjunct to reperfusion therapy for an acute myocardial infarction
50
. 
The GUARDIAN trial
51
 reported that cariporide produced a reduction in the combined end-
point of death and MI, only in the sub-group of patients awaiting cardiac surgery.  
Intravenous diltiazem administered within three hours of acute MI (90 patients) has 
been shown to have beneficial effects on the infarct size, residual viability and recovery of 
regional function by Pizzetti et al
52
. 
 The multicenter DIGAMI trial was performed in diabetic patients who were experiencing 
an acute MI and admitted to the coronary care units (CCUs) of 16 Swedish hospitals between 
January 1990 and December 1993. 1,240 patients were potentially eligible for the study, but 
620 (50%) of the patients were immediately excluded. The remaining 620 patients were then 
randomized to either a control group (314 patients) or an insulin infusion group (306 patients). 
The study was to evaluate the effect of aggressive initial insulin therapy continued for 3 
months on patients' morbidity and mortality following an acute MI. The modest sample size 
and lack of positive findings in other endpoints made this finding less robust. The ECLA group 
reports the largest prospective, randomized trial of GIK for the treatment of AMI ever 
performed and the only such trial done in the era of thrombolytic therapy. Remarkable 66% 
reduction in the relative in-hospital mortality risk was observed when GIK was added to 
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reperfusion (95% of those reperfused had thrombolysis) (252 patients). Survival benefit 
persisted during a 1-year follow-up period in the group that received high-dose GIK plus 
reperfusion as AMI treatment. Despite its being the largest prospective randomized trial of 
GIK to date, the ECLA study is still only 1 trial of GIK, and it is small in comparison with 
contemporary randomized trials of various thrombolytic agents for AMI. Even though this sub- 
group was prospectively stratified and represented 62% of the total number of patients (307 
patients) studied, a conclusion based on a subgroup result is not as convincing as a result 
from the entire study population. In LIMIT-2 trial sixty patients out of 260 patients were 
randomized to magnesium sulphate (8 mmol IV over 15 minutes and 65 mmol over 24 hours) 
or placebo within 12 hours of clinically diagnosed middle cerebral artery stroke. Thirty percent 
of magnesium-treated and 40% of placebo-treated patients was dead or disabled (Barthel 
Index score <60) at 3 months (P=0.42). There was a decrease in the number of early deaths 
in the magnesium-treated group (P=0.066, log-rank test). Further trials are required to 
determine efficacy. The AMISTAD trial was a prospective, open label trial of thrombolysis with 
randomization to adenosine or placebo in 236 patients within 6 hours of infarction onset. 
There was a 33% relative reduction in infarct size (p=0.03) with adenosine. There was a 
significant reduction in infarct size in patients with anterior infarction but no reduction in 
patients with infarcts located elsewhere and the data supported the need for further clinical 
trials. ESCAMI trial was an international, prospective, randomized, double blind, placebo-
controlled phase 2 trial in patients undergoing thrombolytic therapy or primary angioplasty for 
acute ST-elevation myocardial infarction where the effect of eniporide on infarct size and 
clinical outcome was studied. In stage 1, administration of eniporide resulted in smaller infarct 
sizes especially in the angioplasty group. In contrast, in stage 2 there was no difference in the 
enzymatic infarct size between the groups. Overall there was no effect of eniporide on clinical 
outcome and in this large study administration of the NHE-1 inhibitor eniporide, before 
reperfusion therapy in patients with acute ST elevation MI, did not limit infarct size or improve 
clinical outcome. A total of 11,590 patients with unstable angina or non–ST-elevation 
myocardial infarction (MI) or undergoing high-risk percutaneous or surgical revascularization 
were randomized to receive placebo or 1 of 3 doses of cariporide for the period of risk. The 
trial failed to document benefit of cariporide over placebo on the primary end point of death or 
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MI assessed after 36 days. Lower doses had no effect, whereas a high dose was associated 
with a 10% risk reduction and benefit was limited to patients undergoing bypass surgery. No 
significant benefit of cariporide could be demonstrated across a wide range of clinical 
situations of risk. The trial documented safety of the drug and suggested that a high degree of 
inhibition of the exchanger could prevent cell necrosis in settings of ischemia-reperfusion. 
 
1.6 Myocardial Protection by Ischemic Post-conditioning (IPost) 
 
Studies published in the mid-1980s first established that ischemic myocardial injury could be 
reduced, if the myocardial reperfusion process was modified to a staged or gradual form of 
myocardial reperfusion i.e. selective low-pressure (40 to 50 mm Hg) coronary reperfusion with 
normal blood for 20 minutes at 30 ml/min before the occlusion was relieved completely
6
. In 
2003 Vinten-Johansen et al
53
, by interrupting myocardial reperfusion with three cycles of 30 s 
coronary artery re-occlusions, were able to show several beneficial effects including a 44% 
reduction in infarct size, less myocardial oedema, less neutrophil accumulation, reduced 
apoptotic cell death and improved endothelial function.  
The ability of IPost, an intervention that can be applied at the onset of myocardial 
reperfusion to reduce myocardial injury, also provided confirmatory evidence for the existence 
of lethal myocardial injury as an independent mediator of cardiomyocyte death. IPost has 
been shown to target many of the properties of lethal reperfusion injury such as oxidative 
stress, calcium accumulation, inflammation, and mitochondrial permeability transition pore 
(MPTP) opening
54,55
. The mechanism underlying IPost has been intensively investigated, and 
that a signal transduction pathway similar to that recruited by IPC mediating the protection 
has been elicited by post-conditioning. Our group recently discovered common signaling 
pathways that are shared by both IPC and Ipost
56-58
. In this respect a variety of diverse 
pharmacological post-conditioning agents including inhalational anesthetics, G-protein 
coupled receptor ligands such as opioids, adenosine and bradykinin, growth factors such as 
insulin and erythropoietin, natriuretic peptides, adipocytokines, and ‘statins’ have been linked 
to the activation of the reperfusion injury salvage kinase (RISK) pathway, a critical component 
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of this signaling pathway
59
. Ipost can be applied as a cardioprotective strategy in patients 
presenting with acute myocardial infarction.  
 
1.6.1 Ischemic post-conditioning in clinical arena  
 
For patients presenting with an acute myocardial infarction (AMI), IPost can be clinically 
applied at the time of myocardial reperfusion as it can for example in those receiving 
percutaneous intervention (PCI). Studies reporting the clinical application of IPost in patients 
presenting with an AMI were published in 2005
60,61
. Following PCI and stent deployment in 
the infarct-related coronary artery, myocardial reperfusion was interrupted with four-1 min low 
pressure inflations and deflations of the coronary angioplasty balloon and this improved 
myocardial reperfusion, reduced myocardial infarct size both acutely and at 6 months, and 
improved left ventricular ejection fraction at 1 year
60,61
. Jacob Lønborg et al showed a 
tendency toward a better outcome with IPost, by occluding the coronary artery with a balloon 
under low pressure 4 times with each occlusion lasting 30 seconds followed by 30 seconds of 
reperfusion suggesting that IPost is beneficial in achieving complete ST-segment elevation 
(STR), improving New York Heart Association class, reducing infarct size and a better 
ejection fraction at 15 months
62
. The beneficial effect of Ipost in terms of improved left 
ventricular ejection fraction and myocardial perfusion grade were shown by Garcia et al even 
after three years of intervention
63
.  
Studies like Post-conditioning in ST-Elevation Myocardial Infarction (POSTEMI) study 
are under way. POSTEMI is a prospective, randomized, open-label clinical trial with blinded 
endpoints on final infarct size, TIMI myocardial perfusion grade, resolution of ST-segment 
elevation, release of markers of ischemia and left ventricular function
64
.  
  Recent clinical studies have been investigated regarding the potential of Ischemic 
post-conditioning (Ipost) in patients undergoing elective cardiac surgery
65
. However, like IPC, 
this particular cardioprotective strategy requires an invasive protocol of aortic clamping and 
de-clamping. In children undergoing repair for Tetralogy of Fallot (congenital condition), Luo 
et al applied the post-conditioning protocol during the time of de-clamping after the operation.  
This comprised re-clamping the aorta for 30 s and de-clamping it for 30 s, twice just before 
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de-clamping the aorta after the finish of the operation.  They have been shown to reduce 
myocardial injury as evidenced by less peri-operative troponin-T and CK-MB release and 
smaller inotrope requirements post-surgery
65
. A similar protocol has also been demonstrated 
to reduce myocardial injury in adult patients undergoing valve surgery and in children 
undergoing corrective surgery for congenital heart disease using cardioplegia
66
.  Wanjun Luo 
et al showed a reduction in creatine kinase-MB and troponin I, in children scheduled for 
surgical correction of congenital ventricular septal defect, by post-conditioning the heart which 
consisted of 30 seconds of ischemia and 30 seconds of reperfusion achieved by clamping 
and unclamping the aorta, repeated three times over 3 minutes immediately after cardioplegic 
arrest
67
. Clinical application of this could be restricted because of the invasive nature of this 
interventional treatment strategy and the inherent risks of thromboembolism associated with 
aortic clamping and de-clamping. 
 
1.6.2 Pharmacological post-conditioning 
 
Pharmacological post-conditioning means that a variety of pharmacological agents can be 
used to reduce myocardial infarct size when administered at the point of myocardial 
reperfusion. Many of these cardioprotective pharmacological agents exert powerful 
cardioprotection by targeting the reperfusion injury salvage kinase (RISK) pathway at the 
onset of myocardial reperfusion
59
 and by targeting MPTP, a possible end target for protecting 
the heart at the time of myocardial reperfusion
68
.  
Several clinical studies have reported beneficial effects using drugs such as 
adenosine
69
 GLP-1
70,71
 and atrial natriuretic peptide
72
 acting on the RISK pathway or 
cyclosporine-A
73
 which is known to inhibit MPTP opening. Two recent meta-analyses have 
reported the potential benefits of inhalation anesthetics in the setting of cardiac surgery and 
demonstrated better LV function, less troponin release, less inotrope use, shorter ventilation 
time and shorter hospital stay
74,75
. 
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1.7 Myocardial Protection by remote Ischemic conditioning (RIC) 
 
By applying brief episodes of non-lethal ischemia and reperfusion to an organ or tissue 
remote from the heart it has been shown that cardioprotection can be achieved. This 
phenomenon has been termed remote ischemic ‘conditioning’. By applying remote ischemic 
conditioning widespread systemic protection can be offered to other organs, which are 
susceptible to acute ischemia–reperfusion injury such as the brain, liver, intestine or kidney. 
In 1993, Przyklenk et al
76
 showed that by applying short episodes of myocardial ischemia and 
reperfusion to the left anterior descending coronary territory, they were able to subsequently 
reduce the size of a myocardial infarct generated in the circumflex coronary artery territory 
and this  phenomenon was termed ‘regional ischemic preconditioning’.  
Subsequently came the exciting ‘remote ischemic preconditioning’ (RIPC), where the 
preconditioning protocol could be applied to organs and tissues distant or remote from the 
heart such as the kidney or small intestine
77,78
. The underlying mechanism remains unclear 
though many of the signaling pathways underlying myocardial preconditioning and post-
conditioning have been implicated in RIPC. It has been proposed that substances released 
from the preconditioned organ or tissue such as adenosine, bradykinin or opioids stimulate 
local afferent nerves pathways, which then activate efferent nerve pathways, which then 
terminate on the myocardium. Another suggestion is that a substance or humoral factor is 
carried in the blood stream to the heart where it manifests its protective effect.  
Kerendi et al’s experimental studies suggest that remote ischemic conditioning can 
be effective even if applied after the onset of myocardial ischemia—a phenomenon which has 
been termed remote IPost
79
.  Using an anaesthetized rat, they demonstrated that applying a 5 
min episode of renal ischemia followed by 5 min of renal reperfusion after the onset of 
myocardial ischemia and immediately before myocardial reperfusion was capable of reducing 
myocardial infarct size, through a mechanism which required binding to an adenosine 
receptor
79
. 
Subsequent experimental studies have confirmed the presence of RIPost as a viable 
cardioprotective intervention in the rabbit
80
 and porcine hearts
81
 using limb ischemia as the 
RIPost stimulus.  
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Schmidt et al showed a reduction in myocardial infarction size by applying short 
periods of limb ischemia during the time of well established myocardial ischemia and called it 
as “remote perconditioning”
82
. Recently Loukogeorgakis et al have reported improvement in 
endothelial function in patients with stable coronary artery disease, using upper limb ischemia 
as the remote post-conditioning stimulus and contra lateral upper limb endothelial function as 
the indicator of protection
4
. Very recently our group has reported a decrease in the incidence 
of Acute Kidney Injury (AKI) in non-diabetic patients undergoing elective CABG surgery in a 
retrospective analysis where RIPC consisted of three 5-minute cycles of right forearm 
ischemia, induced by inflating a blood pressure cuff on the upper arm to 200 mm Hg, with an 
intervening 5 minutes of reperfusion
83
.  
 
1.7.1   Remote ischemic preconditioning in clinical arena 
 
By applying electrical stimulation to the lower limb skeletal muscle of rabbits
84
 Birbaum et al 
found that remote ischemic preconditioning could be elicited and this was pivotal in terms of 
the clinical application of this cardioprotective phenomenon. Though in a small clinical study 
comprising only eight patients undergoing CABG surgery, RIPC using lower limb ischemia 
was found not to be cardioprotective
85
.  
Pioneering work by MacAllister and colleagues characterized a non-invasive RIPC 
protocol in human volunteers which involved an automated cuff placed on the upper arm to 
induce brief episodes of forearm ischemia and reperfusion and endothelial function was 
measured as the end-point
86
. Subsequent clinical studies by our laboratory and others have 
demonstrated reduced myocardial injury in terms of cardiac enzyme release in the settings of 
both cardiac surgery
87
.  
A small clinical study examined the role of RIPC in patients undergoing low-risk 
elective PCI and paradoxically, they reported myocardial injury to be increased
88
. However, a 
larger and robust clinical study with 242 patients undergoing elective PCI, elicited a reduction 
in troponin-I in patients receiving the RIPC protocol
89
. 
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A recent meta-analysis comprising of 22 clinical trials and 933 patients
90
 reported 
fewer ventricular arrhythmias, smaller inotrope requirements and shorter stays on the 
intensive care unit in patients treated with RIPC. 
 
1.8 The Mitochondrial Permeability Transition Pore (MPTP) 
 
The mitochondrial permeability transition pore (MPTP) is a voltage dependent proteinaceous 
pore of the inner mitochondrial membrane (IMM) and on opening mediates the mitochondrial 
permeability transition (MPT). This describes the abrupt increase in permeability of the inner 
mitochondrial membrane which takes place in response to various inducing factors like high 
matrix calcium, oxidative stress, high phosphate and low adenine nucleotides
91-93
. The idea of 
an actual inner mitochondrial membrane proteinaceous pore (MPTP) was first described in 
the late 1970’s by Haworth and Hunter
91-93
 as a “Ca
2+
-Induced Membrane Transition in 
Mitochondria. 
Opening of MPTP allows free passage of molecules <1.5 kDa disrupting the 
permeability barrier of the IMM. This allows the free movement of proton across the IMM 
causing uncoupling of oxidative phosphorilation and eventually hydrolysis of ATP. The 
mitochondrial pores are either fully open or closed and once they are fully opened the 
mitochondria swell extensively
94
. 
 
 
1.8.1 Characterisation of the Mitochondrial Permeability Transition Pore  
 
 
After nearly two decades of studies on mitochondria, the following various phenomena were 
discovered separately and considered as independent events: Swelling of mitochondria in 
isotonic medium in the presence of calcium causing – uncoupling, inhibition of ATPase 
activity, swelling and inhibition of respiration, as well as protection by EGTA or phosphate 
against uncoupling and swelling and loss of nucleotides, Krebs cycle intermediates and 
Coenzyme A. Later it was recognised that the above phenomenon were manifestations of the 
same process that is MPTP
95
. 
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By 1980, Haworth and Hunter characterised many of the key features of the MPTP 
7,91-93
. According to them the MPTP was unselectively permeable to H
+
, Ca
2+
 Mg
2+
, choline, 
glucose, sucrose, and NAD(P)H and that the MPTP opening was a reversible process. On 
determining the size of the pore they used dextrans of different molecular weight and 
postulated the molecular cut-off to be <1500 Da
91
. Subsequent studies by Crompton’s group 
examining the permeability of the MPTP to [
14
C] solute fluxes, calculated that the MPTP had a 
diameter of 2.0-2.6 nm
96,97
. They proposed that the adenine nucleotide translocase (ANT) 
might be part of the MPTP based on the finding that the MPTP could be opened by 
atractyloside and closed by bongekrekic acid both known to act on the ANT, and that MPTP 
opening was sensitive to ADP
7,91-93
. They also postulated that the components of MPTP might 
form at contact sites between the inner and outer mitochondrial membranes.  
 A number of inducers and inhibitors of MPTP opening have been described and the 
following provides the important known inducers and inhibitors: 
 
1.8.1.1  Inducers of MPTP Opening 
 
1.8.1.1.a Calcium and Phosphate 
The rise in intracellular Na
+ 
is due to he increased generation of protons during ischemia, via 
Na
+ 
- H
+
 exchanger (NHE)
98
 and also due to Na
+
 entering the cell during ischemia
99
. This 
results in the reversal of Na
+ 
- Ca
2+
 exchanger (NCX) leading to the rise in cytosolic Ca
2+100
. 
Studies have shown that a rise in cytosolic free calcium concentration ([Ca
2+
]i) preceded 
irreversible myocardial injury and that drugs that reduced or delayed this rise in cytosolic 
[Ca
2+
]i also reduced or delayed myocardial death
98,100-102
. Though some studies have reported 
that a rise in cytosolic calcium was not important
103
, the majority of recent studies have shown 
that a rise in [Ca
2+
]i precedes irreversible injury and that blockage of this rise in [Ca
2+
]i  can 
attenuate or delay the onset of irreversible injury
101,104,105
.  
  MPTP is triggered by calcium overload especially when this is accompanied by 
oxidative stress and these two parameters appear critical determinants of the recovery of 
isolated heart cells from simulated ischemia and is believed that calcium induces MPTP 
opening by binding to two activating sites on the matrix side of the pore
91,106
. Ca
2+
-induced 
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MPTP opening can be facilitated in the presence of MPTP inducers such as P i, a weak acid 
that allows the accumulation of enormous amount of mitochondrial Ca
2+ 
up-take by providing 
a mechanism for reducing matrix alkalinisation. Pi must enter the matrix to exert its effect, 
which might be due to its ability to buffer the matrix pH or by causing a reduction in the matrix 
ADP. In fact the extent of recovery of the cell has been reported to correlate inversely with 
mitochondrial matrix calcium concentrations at the end of ischemia
107,108
 and to be triggered 
by the rise in ROS during reperfusion
103
. However, more recent data from Bernardi's 
laboratory has suggested that Pi actually inhibits (rather than activates) pore opening. They 
also suggested that this effect is overcome by the presence of CyP-D, accounting for the 
protective effects of CsA in the presence of Pi and hence argued against a role for the PiC in 
the MPTP. These authors assayed the calcium retention capacity (CRC) of energised liver 
mitochondria from wild-type and CyP-D knockout mice
109,110
. 
 
1.8.1.1.b Oxidative Stress 
The role of reactive oxygen species (ROS) in ischemia-reperfusion injury has been 
extensively studied and ROS has been measured using electron spin resonance (ESR)
111,112
 
and by using fluorescent indicators
113,114
. During reperfusion, with the return of oxygen, a 
large burst of ROS generation have been consistently demonstrated by several studies
114,115
. 
This increase in ROS during ischemia and reoxygenation is thought to be due to damage to 
electron transport chain components resulting in inefficient transfer of electrons, generating 
superoxide. Kim et al, have reported that ROS generated during early reperfusion is the 
primary activator of the MPTP and cardiomyocyte death
103
.  
Mitochondria are thought to be both a major source of ROS as well as a major target 
for ROS damage. Mitochondrial electron transport is one of the primary sources of ROS 
production in the cell and ROS are generated during electron transport at complexes I and III.  
The low levels of ROS that are generated during ischemia can damage the electron transport 
chain
116
. Inhibition of electron transport (particularly complex I) reduces ROS generation 
during ischemia and mitochondrial uncouplers have been shown to reduce ischemia-
reperfusion injury
116
.  
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Opening of the MPTP can be induced by: (1) Endogenous ROS - Reactive oxygen 
species (ROS) generated by the mitochondrial electron transport chain, xanthine oxidase, and 
NADPH oxidase; (2) Exogenous sources of ROS; and (3) Oxidising agents such as t-
butylhydroperoxide. Oxidative stress induces MPTP opening by oxidising critical thiol groups 
of the inner mitochondrial membrane (IMM) to form thiol cross-linkage. Thiol agents such as 
phenylarsenine oxide, hydroperoxides and diamide induce MPTP opening by cross-linking 
inner membrane thiol groups. Halestraps’ group have postulated that these agents induce 
MPTP opening by cross-linking Cys160 and Cys257 of the ANT
117
.  
 
1.8.1.1.c Thiol Reagents 
Bernardi's group confirmed the contribution of thiol groups to MPTP opening, showing both 
the protective (at low concentration) and the inducing (at higher concentration) effects of N-
ethylmaleimide (NEM)
118
.  
 
1.8.1.1.d Fatty Acids 
Fatty acids diffuse into the mitochondria as the protonated electroneutral form and act as 
classical uncouplers, inducing MPTP opening by decreasing the transmembrane potential
119
. 
Petronilli et al also showed a possible direct interaction of fatty acids with the MPTP
120
. 
 
1.8.1.1.e Adenine Nucleotide Translocator Ligands 
ANT ligands can act either as MPTP inducers or inhibitors. Atractyloside and 
carboxyatractyloside, which stabilise the ANT in the ‘c’ conformation (with the adenine 
nucleotide binding site facing the cytosol) favour MPTP opening
121
 and bongkrekate, which 
stabilise the ANT in the ‘m’ conformation (with the adenine nucleotide binding site facing the 
matrix) inhibit MPTP opening
91
. 
 
1.8.1.1.f Acyl-CoA 
The effect of acetyl-CoA on MPTP opening is reported to depend on their side of attachment 
to ANT, that is by acting either from the outer or inner side of the membrane
122
. Bernardi et al 
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proposed an alternative explanation for the acyl-CoA’s action and accounted for by the 
variations in membrane surface potential
94
. 
 
1.8.1.1.g Arachidonic acid 
In isolated mitochondria arachidonic acid stimulates MPTP opening and in intact cell it causes 
cell death due to intracellular calcium overload, most likely reflecting mPTP opening 121
123
. 
 
1.8.1.2  Inhibitors of MPTP Opening 
 
1.8.1.2.a Cyclosporin-A 
Following the lead by Fournier and colleagues in late 1980s
124
, Crompton’s group
125
 and 
Pfeiffer’s groups
126
 reported that cyclosporine-A (CsA), the immunosuppressive agent, 
strongly prevented the opening of MPTP at sub-micro molar concentrations by inhibiting 
mitochondrial Ca
2+
 efflux and allowing mitochondria to accumulate large amounts of Ca
2+
. 
Nazareth et al
127
 demonstrated protection with CsA using an isolated cardiac myocyte model 
of anoxia and reoxygenation, and, subsequently, this has been confirmed by others
128,129
. The 
protective effect of CsA in the Langendorff-perfused heart model of reperfusion Injury was 
shown by Halestrap’s group
130,131
. In the presence of CsA, the recovery of haemodynamic 
function during reperfusion was greatly improved, as reflected by higher left ventricular 
developed pressure (LVDP) and lower end diastolic pressure (EDP), and reduced release of 
intracellular lactate dehydrogenase. Using a chromatography affinity binding column, 
Halestrap’s group
132
 demonstrated that a fusion protein between cyclophilin D and 
glutathione-S-transferase (GST) bound to ANT in response to the thiol, diamide, and the 
binding was inhibited by CsA, suggesting that CsA inhibited MPTP opening by preventing the 
binding of cyclophilin D to ANT
132
. The effect of CsA on the MPTP is described as 
‘desensitization’ by Bernardis group and the inhibitory effect of CsA can be overcome by 
increasing Ca
2+ 
load
94,131,133
. Lemaster’s group proposed the existence of an unregulated 
CsA-insensitive form of MPTP opening
134
.  
Recently in a proof-of-concept clinical study, a single bolus of cyclosporine-A (CsA) 
administered to patients presenting with an acute MI just prior to primary coronary 
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angioplasty, was reported to reduce myocardial infarct size by 30–40%
135
. Of interest, the 
recent studies using an in vivo porcine model of ischemia reperfusion injury have produced 
mixed results where the cardioprotective effect of isoflurane is abolished by the combined 
usage of isoflurane and CsA
136
. Following cardioplegic arrest in a neonatal rabbit model, 
Leung et al by demonstrating CsA-sensitive MPTP opening at the time of myocardial 
reperfusion suggested that application of CsA or another MPTP inhibitor may be beneficial in 
terms of reducing perioperative myocardial injury in neonates undergoing corrective cardiac 
surgery
137
. Cour and colleagues using a rabbit model found improved survival, reduced 
myocardial necrosis and inhibited MPTP opening in isolated cardiac mitochondria following 
administering either intravenous CsA (5 mg·kg-1) or N-methyl-4- isoleucine cyclosporin 
(NIM811) (2.5 mg·kg-1) at the time of reperfusion following a 15 min period of primary 
asphyxia in situ cardiac arrest
138
. 
 CsA, as well as inhibiting MPTP opening, can inhibit the protein phosphatase 
calcineurin through its binding to cyclophilin A. This has resulted in the use of CsA analogues 
such as N-methyl 4-valine CsA and N-methyl-4-iosleucine-CsA (NIM811), which inhibit MPTP 
opening without inhibiting calcineurin. A new MPTP inhibitor called sanglifehrin-A has been 
described which also inhibits MPTP opening without inhibiting calcineurin
139
.  
 
1.8.1.2.b Sanglifehrin-A 
Using the langendorff-perfused heart model, Halestrap’s group have characterised a newer 
MPTP inhibitor called sanglifehrin
139,140
, an immunosuppressant which differs from CsA in that 
it does not inhibit calcineurin
141,142
. The mechanism of MPTP inhibition by SfA also differed 
from that of CsA. SfA was demonstrated to bind to and inhibit the PPIase activity of 
cyclophilin D (Ki of about 2.2 nmol/l) but unlike CsA, SfA did not prevent the binding of 
cyclophilin D with ANT
139
. The concentration-dependence of SfA’s inhibition of the MPTP is 
sigmoidal compared to the linear dependence of CsA. Using the isolated perfused rat heart 
Halestrap’s group demonstrated that inhibiting MPTP opening using SfA (at 1.0 µmol/l) 
protected the heart against ischemia-reperfusion injury. They demonstrated using above 
experiment an attenuated LDH release and improved recovery of left ventricular contractile 
function
139
. 
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Limitation in the use of CsA and SfA as inhibitors of the MPTP is that both CsA and 
SfA fail to inhibit MPTP opening when mitochondria are exposed to a sufficiently strong 
stimulus
139,143
 such as elevated matrix calcium, oxidative stress, and adenine nucleotide 
depletion that accompany reperfusion after a period of ischemia
11,144
.  
 
1.8.1.2.c Bongkrekic acid and ubiquinone derivatives 
It has been demonstrated that bongkrekic acid (BKA) is a potent inhibitor of the MPTP in 
isolated mitochondria and also been reported of its use to inhibit pore opening in cultured 
cells
145,146
 including cardiac myocytes
147,148
. Bongkrekic acid acts by inhibiting the export of 
ATP from the mitochondria to the cytosol and hence its action has been questioned.   
Bernardi’s group have demonstrated that substrates which increase electron flow 
through the complex I of the electron transport chain compared to complexes II and IV, 
sensitise the MPTP to Ca
2+
, and therefore ubiquinone analogues which act to inhibit electron 
flow through complex I can inhibit MPTP opening. 
 
1.8.1.2.d Divalent and trivalent Cations 
Divalent cations such as Mg
2+
, Sr
2+
, Mn
2+
, Ba
2+
 can inhibit MPTP opening by competing with 
Ca
2+
 for its activating site on the MPTP and Sr
2+
 and Mn
2+
 have been shown to exert an 
inhibitory effect at a matrix-side site. Alternatively, these ions may inhibit MPTP opening by 
binding to an alternative site on the cytosolic side of the MPTP
149
. 
 
1.8.1.2.e Pyruvate and Propofol 
Reducing oxidative stress by the use of free radical scavengers has been shown to offer 
some protection against reperfusion injury
150
. Radical scavengers may directly inhibit the 
opening of the MPTP by preventing oxidative cross linking of critical cysteines on the ANT
146
 
or by indirect effect on the MPTP opening, as oxidative stress is known to inhibit plasma 
membrane ion pumps, leading to perturbation of ionic homeostasis and calcium overload.  
Halestrap’s group have investigated the effects of two free radical scavengers on 
MPTP opening, namely pyruvate
151
 and the anesthetic propofol
152
 and showed improved 
functional recovery of hearts during reperfusion. They also demonstrated that all the ‘‘open’’ 
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mitochondria subsequently resealed as the reperfusion continued
151
. The ability of pyruvate to 
protect hearts and other tissues may be mediated by its free radical scavenging activity
153
. 
Also unlike glucose or glycogen, pyruvate does not require ATP for activation before its 
metabolism. Cross et al, using nuclear magnetic resonance (NMR) studies, showed that 
pyruvate can lead to a decrease in pH
154
 and hence inhibit MPTP. Propofol has been shown 
to protect the heart against reperfusion injury, in a langendorff-perfused rat heart model,
155
 
and also against damage caused by H2O2-induced oxidative stress
156
. Halestraps group using 
the 3H-DOG technique has confirmed that the protection offered by propofol is accompanied 
by less opening of the MPTP
152
. Moreover to match the clinical practice, Halestrap’s group 
used an in vivo pig model of cardiopulmonary bypass with warm blood cardioplegia, and 
showed that propofol could improve functional recovery of the heart, reduce troponin-I 
release, and maintain higher tissue ATP levels
157
. 
 
1.8.1.2.f Local anaesthetics and Phenothiazines 
The phenothiazine, trifluoperazine was originally thought to inhibit MPTP opening by 
competing with Ca
2+
 for its binding site on the MPTP
149
. However, it also has many non-
specific effects, which include inhibition of calmodulin, and it also inhibits the F1F0ATPase. 
Later studies have suggested that it may modify the voltage sensitivity of the MPTP
158
. Local 
anesthetics agents bind to phospholipid Ca
2+
 binding sites on biological membranes, 
displacing Ca
2+
 in a competitive manner. 
 
1.8.1.2.g Adenine Nucleotides 
The evidence of the involvement of the ANT in MPTP formation comes from the effects of 
oxidative stress and thiol reagents to enhance MPTP opening by acting both by decreasing 
adenine nucleotide binding and inhibition of MPTP opening and by increasing CyP-D 
binding
159
. Halestrap’s group have showed that inhibition of MPTP opening by high 
membrane potential works by increasing matrix adenine nucleotide binding to the ANT
159
. The 
binding of ATP (to the cytosolic side of the ANT) and the binding of ADP (to the matrix side of 
the ANT) inhibits MPTP opening. Binding of ADP competes for the Ca
2+
-activating site on the 
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MPTP
91
. Novgorodov et al confirmed that the affinity of calcium for the activating site was 
decreased by ADP
106
. 
 
 1.8.1.2.h Oligomycin 
The protective effect of oligomycin could be due to either an increase in matrix ADP content
160
 
or an increase in the transmembrane potential attributed to an inhibition of the proton leaks 
through the ATP synthetase
161
. 
 
1.8.2 The Molecular Identification of the MPTP 
 
The all-or-nothing character of the MPTP convinced Hunter and Haworth that the permeability 
transition resulted not from the degenerative process but from the opening of a bona-fide pore 
MPTP
91-93
. Following their work, Crompton and co-workers showed that the permeabilisation 
process could be immediately interrupted by EGTA
162-164
. Crompton et al proposed that the 
pore of each mitochondrion opened or closed with high degree of synchronisation
96
. Definitive 
evidence for the involvement of a bona-fide pore in the permeabilization process came from 
electrophysiological patch-clamp studies in 1989 where a large 1.3 nS (in 150 mmol/l KCl) 
multi-state channel in the inner mitochondrial membrane was identified
165
 as MPTP. It was 
estimated that the MPTP diameter would be 2-3 nm. The actual molecular composition of the 
MPTP is currently unknown
166
 though several models have been proposed. 
 
1.8.2.1  Possible Components of the MPTP 
 
1.8.2.1.a Adenine Nucleotide Translocase 
In 1979, Haworth and Hunter first proposed that the ANT might be part of the MPTP, based 
on their findings that MPTP opening was sensitive to ADP, and to the ANT inhibitors 
atractyloside and ANT in MPTP formation and proposed that MPTP inducers such as 
atractyloside, carboxyatractyloside, a high NADP/NADPH ratio, and fatty acids stabilised the 
‘c’ conformation (where the nucleotide-binding site is on the cytosolic side) of the ANT and 
MPTP inhibitors such as bongkrekic acid and matrix ADP stabilised the ‘m’ conformation 
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(where the nucleotide-binding site is on the matrix side)
167
. Halestrap and co-workers 
proposed that ANT adopts an open pore conformation upon binding with Calcium and 
cyclophilin and that binding of both Calcium and cyclophilin is required for MPTP opening. 
They suggested that the ANT was the sesitisator of MPTP to calcium by oxidative stress and 
the vicinal thiol reagent phenylsarsine oxide (PAO) 
159
. Halestrap’s group first proposed and 
have subsequently demonstrated that cyclophilin D induces the conformational change in 
ANT to form the MPTP in a CsA sensitive manner
117,131,168
.    
However the requirement of ANT as an essential component has been seriously 
questioned by the results obtained from mice lacking ANT
169
. They found that CsA inhibition 
of MPTP in mice lacking ANT could still be detected but it required a larger Ca
2+
 load. 
Therefore they proposed that ANT might play a regulatory role and is not essential to be a 
component of MPTP and also ANT is not the receptor for cyclophylin D
169
. They also found 
that MPTP in ANT-null mitochondria was not sensitive to opening by atractyloside and to 
closure by ADP. One of the possible explanation for this, is that ANT could be the normal 
membrane component of MPTP but the other less abundant members of the mitochondrial 
carrier family can fulfil this role in the absence of ANT
170
. LeMasters group proposed an 
alternative possibility in that ANT is the most abundant proteins in the unfolded proteins that 
form the MPTP
134
. Also Dejean et al showed that the up-regulation of the uncoupling protein-3 
induced sensitization of the MPTP to calcium, suggesting that inner membrane transporters 
other than the ANT may also regulate mitochondrial permeability transition
171
. 
  
1.8.2.1.b Cyclophilin D 
It has been generally accepted that cyclophilin D, a peptidyl-prolyl cis-trans isomerase, 
facilitates the calcium triggered change in conformation of an inner mitochondria membrane 
component
172
. Crompton et al were the first to suggest the role of CyP-D in the interaction of 
MPTP as they discovered that cyclosporin A acted as a potent inhibitor of pore opening
125. 
Different CsA analogues were also shown to inhibit MPTP opening, thereby correlating their 
ability to inhibit the peptidyl prolyl cis-trans isomerase activity within the matrix
168,173
 and this 
was subsequently identified as CyP-D
174,175
. Using CyP-D knockout mice, matrix peptidyl-
prolyl cis-trans isomerase activity of cyclophilin D was subsequently confirmed using CsA and 
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SfA to inhibit MPTP opening by some authors
176,177
. Mitochondria have been demonstrated to 
contain a CsA-sensitive PPIase, which has been purified and cloned
176,177
. Lemasters et al 
proposed a chaperone like property to CyP-D and proposed that MPTP would be formed by 
clusters of misfolding proteins in a process prevented by CyP-D
134
.  
Recently our group reported that the CYP-D component of the MPTP is critical to IPC 
protection as it is required to generate mitochondrial ROS, which in turn activates the 
important mediatory protein kinases, Akt, and Erk1/2
178
. Murphy’s group showed that Cys-203 
residue of CyP-D is necessary for redox stress-induced activation of MPTP using mouse 
embryonic fibroblasts
179
. 
 
1.8.2.1.c Voltage-Dependent Anion Channel 
In 1994 Zoratti et al
180
, proposed that the Voltage activated anion channel (VDAC, also known 
as porin) might be involved in the formation of the MPTP. The MPTP has been proposed to 
form at contact sites between the inner mitochondrial membrane (IMM) and outer 
mitochondrial membrane (OMM)
181
 and VDAC has been shown to form at these contact 
sites
182,183
. In 1998 Crompton et al showed the involvement of VDAC in MPTP formation
184
 by 
suggesting that CyP-D can bind strongly to both VDAC and ANT. This cyclophilin D-VDAC-
ANT complex was incorporated into liposomes and demonstrated MPTP activity in response 
to Ca
2+
 and Pi which was blocked by CsA
184
. 
 Bernardi’s group in their initial report suggested that VDAC might be the locus for 
inhibition by ubiquinone analogues
185
, however recently the liver mitochondria from mice 
lacking VDAC1 exhibited normal MPTP opening and inhibition by ubiquinone analogues
186
 
suggesting that VDAC1 could be unlikely to be a component of MPTP. Moreover Baines’s 
experiment have raised doubts regarding VDACs involvement in MPTP, as the three VDAC 
isoforms knockouts continue to express MPTP activity
187
. However, Marco Colombini has 
demonstrated that closure of VDAC actually increases Ca2+ flux
188
 which would suggest that 
closure of VDAC should actually promote opening of the MPTP. This was supported by 
Tikunov et al who utilized G3139, a phosphorothioate blocker of VDAC, to cause VDAC 
closure and opening of MPTP
189
. However VDAC continues to be purported as part of the 
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MPTP mechanism in normal cells and were even proposed to be directly responsible for 
cytochrome c release
190-193
. 
 
1.8.2.1.d The mitochondrial phosphate carrier (PiC) 
Halestraps group have recently proposed a model for the MPTP in which the pore forming 
component is the PiC rather than the ANT
194
. PiC can be inhibited by ubiquinone analogues 
and by N-ethylmaleimide (NEM), which is a potent inhibitor of MPTP opening at low 
concentrations. PiC undergoes a calcium-triggered conformational change which is facilitated 
by the peptidyl–prolyl cis–trans isomerase activity of CyP-D and this allows for MPTP opening 
even in the absence of CyP-D or the presence of CsA but at a much higher calcium load that 
was observed
131,195-197
. This calcium induced conformational change might be enhanced by 
an interaction of the PiC with the “c” but not the “m” conformation of the ANT
177,178,194
. 
Kokoszka et al have demonstrated pore opening in mitochondria containing no ANT1 or 
ANT2, but with reduced sensitivity to calcium and no sensitivity to ligands of the ANT
169
. 
Further evidence comes from Krämer and colleagues, where they demonstrated that the PiC 
of yeast mitochondria can be converted into a non-specific anion channel
198
.  
However, more recent data from Bernardi's laboratory has suggested that Pi actually 
inhibits (rather than activates) pore opening. They also suggested that this effect is overcome 
by the presence of CyP-D, accounting for the protective effects of CsA in the presence of Pi 
and hence argued against a role for the PiC in the MPTP. These authors assayed the calcium 
retention capacity (CRC) of energised liver mitochondria from wild-type and CyP-D knockout 
mice
109,199,200
. 
   
1.8.3 The MPTP opens during reperfusion and not during ischemia 
 
 
Halestarp’s group in 1995, demonstrated that the MPTP was kept firmly closed in the heart 
under normal physiological conditions but opened upon reperfusion following a period of 
ischemia
143
. They used a technique that involved the entrapment of [
3
H]-2-deoxyglucose in 
the mitochondria that has undergone transition
143
. Our group, by measuring the MPTP 
opening using fluorescent microscopy in isolated cardiac myocytes, showed that the MPTP 
opens upon reperfusion in a setting of ischemia and reperfusion
201
. Opening of MPTP at 
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reperfusion is also supported by Lemaster’s group
103
 and they demonstrated MPTP opening 
occurring at the time of reoxygenation, in hepatocytes subjected to periods of simulated 
ischemia. In this model MPTP opening was indicated by the entry of the membrane-
impermeant fluorescent dye calcein and mitochondrial membrane depolarisation
202
. Di Lisa’s 
group
203
 demonstrated the same finding using the CsA-sensitive loss of mitochondrial NAD+, 
that occurred during the first few minutes of reperfusion to indicate MPTP opening. 
 Very recently Duchen et al devised an approach that delivers Ca
2+
 directly to the 
matrix of mitochondria independently of uptake and therefore independently of potential 
(Δψm) and this allows direct study both of the Ca
2+ 
efflux pathway and of the specific 
sensitivity of MPTP to Ca
2+
 in intact and in permeabilized cells
204
. Duchen et al achieved this 
using the photolytic release of Ca
2+
 by flash photolysis of caged Ca
2+
 using compounds, such 
as o-nitrophenyl EGTA, introduced into the cell as the acetoxymethyl (AM) ester (NP-EGTA, 
AM)
204
. 
 During ischemia the low pH (<7), a powerful inhibitor of MPTP, keeps the pore closed 
and the return of pH to normal during reperfusion induces pore opening
205
. It is the low pH 
accompanying ischemia that prevents the MPTP opening despite the conditions where MPTP 
inducers are present
151
. Hence, maintaining a low pH during the initial phase of reperfusion 
following an ischemia is shown to protect the heart from reperfusion injury
206
.    
 During ischemia, the rise in cytosolic Ca
2+
 begins when about two-thirds of cellular 
ATP has been depleted and this rise in cytosolic Ca
2+ 
results in mitochondrial Ca
2+
 loading 
and MPTP opening, suggesting that the mitochondrial [Ca
2+
] is a critical determinant of MPTP 
opening and cell death
207
. During reperfusion the rapid energisation of the mitochondria will 
lead to electrogenic calcium uptake into the mitochondria from the cytosol inducing MPTP 
opening
12
. However, experiments carried out in isolated cardiac myocytes showed that it is 
the mitochondrial calcium that was responsible for MPTP opening
108
. Furthermore the surge 
of ROS production during reperfusion is one of the most important factors determining the 
outcome of reperfusion. 
Recently our group demonstrated that the MPTP can reversibly open in adult 
cardiomyocytes under basal conditions, and that this form of MPTP opening is augmented by 
hypoxic preconditioning
178
. 
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1.8.4 Consequences of MPTP Opening  
 
Along with increased matrix swelling MPTP opening results in major modifications of 
mitochondrial function and structure that ultimately affect the maintenance of the cell viability. 
The immediate effect of the MPTP opening is the collapse of the mitochondrial membrane 
potential and opening of MPTP results in both apoptotic and necrotic cell death.   
 
1.8.4.1  MPTP opening and Necrotic Cell Death  
Once the pore opens it allows free passage of protons across the inner membrane leading to 
a dissipation of the membrane potential and pH gradient comprising the proton motive force. 
Maintaining the relative impermeability of the inner mitochondrial membrane is critical to ATP 
production, as it permits the generation of this electro-chemical gradient - the chemiosmotic 
hypothesis first described by Mitchell & Moyle
208
. Therefore, the abrupt permeation of the IMM 
allows entry of protons into the mitochondrial matrix, which dissipates the proton-mediated 
mitochondrial membrane potential. This halts ATP production and results in ATP hydrolysis 
as the F0F1-ATPase complex (reverse operation) breaks down ATP in an attempt to maintain 
the mitochondrial membrane potential leading to ATP depletion
209,210
. 
When the tissue ATP levels become severely compromised and, left unchecked, these will 
lead to major perturbations in the ionic and metabolic homeostasis of the cell leading to 
necrotic cell death through the activation of phospholipases, nucleases and proteases
12,166,210
. 
Opening of the MPTP is associated with loss of matrix Ca
2+
, depletion of reduced glutathione, 
depletion of NADPH, and the hypergeneration of superoxide anion. More recent data have 
begun to suggest that necrosis may be ‘‘programmed’’ and is not a default ‘‘accidental’’ 
pathway
211-213
. 
 The importance of the MPTP in the necrotic death using MPTP inhibitors such as 
cyclosporin A and sanglifehrin A have been demonstrated in the heart, brain and 
liver
130,139,202,214
. More recently, it has been shown that CyP D dependent MPTP plays an 
important role in some forms of necrotic cell death. Nakagawa and Baines groups 
demonstrated that CyP D-deficient embryonic fibroblasts (MEFs) show significantly increased 
resistance to H2O2- induced necrosis
195,197
 and CyP D-deficient hepatocytes showed 
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resistance to necrosis induced by a Ca
2+
 ionophore (A23187) or by H2O2
195,197
. Interestingly 
when necrosis was inhibited by CyP D deficiency, apoptosis did not occur as an alternative 
death mechanism
197 suggesting that the H2O2/Ca
2+
- induced apoptotic signalling pathways 
are somehow blocked in these types of cells. 
 
1.8.4.2  Apoptotic Cell Death and MPTP 
 
Another consequence of MPTP opening is mitochondrial matrix swelling and this may lead to 
apoptotic cell death under some conditions. Swelling of the mitochondria occurs as the MPTP 
is permeable to all solutes of sizes <1.5 kDa and the non-protein components of the 
mitochondrial matrix will rapidly equilibrate across the IMM. However, the matrix proteins 
remain inside the mitochondria and their higher concentrations exert a colloidal osmotic 
pressure causing the matrix to swell. This unfolds the cristae in the IMM without breaking the 
IMM, but the outer membrane ruptures allowing the contents of the inter membrane space to 
be released including cytochrome c and other proapoptotic proteins such as Smac/Diablo and 
Apoptosis Inducing Factor (AIF). Thus, even if MPTP opening is insufficient to deplete ATP 
levels and cause necrosis, apoptosis may result
12,166
. However, the release of pro-apoptotic 
proteins from the inter membrane space is normally mediated by specific permeabilisation of 
the outer membrane through the action of pro-apoptotic members of the Bcl-2 family such as 
Bax
215,216
. 
Caspases activation is thought to be a major mechanism of apoptotic cell death and 
their role in ischemia-reperfusion injury has been debated
217,218
. Authors have reported that 
inhibition of caspases can only result in a modest reduction in infarct size
218
. However, a large 
number of studies demonstrated that addition of caspase inhibitors reduced infarct size, 
suggesting an important role for caspase activation in ischemia-reperfusion injury
219,220
. 
Caspase 9 are activated during ischemia, whereas caspases 8 and 9 are activated during 
reperfusion
220
. It has also been suggested that inhibition of caspases promotes necrotic cell 
death
221
. 
 Inhibiting mitochondrial membrane permeability (MMP) using MPTP inhibitors such as 
cyclosporine-A or bongkrekic acid have been demonstrated to inhibit apoptotic cell 
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death
222,223
. At low doses Bax was demonstrated to induce permeabilisation of the OMM only, 
though at higher doses it also induced the permeabilisation of the IMM. MPTP opening in this 
setting will result in ATP depletion, which would be expected to halt the energy-dependent 
apoptotic process, so it appears counter-intuitive to have MPTP opening in apoptotic cell 
death.  
Furthermore, mitochondrial swelling and OMM rupture does not always occur in 
apoptotic cells, and mitochondrial cytochrome C release can occur independent of MPTP 
opening
224,225
. Therefore, MMP may occur by a direct action of pro-apoptotic protein on the 
OMM, independent of the MPTP. Studies have shown that over expression of CyP D, inhibits 
apoptosis induced by over expression of caspase-8 (but not Bax) or by exposure to arsenic 
trioxide
226,227
. There is a possibility that these forms of apoptosis are mediated by the MPTP 
and they are somehow affected by CyP D over expression. Baines et al showed that cardiac 
myocytes isolated from transgenic mice with myocardial expression of CyP D did have a 
tendency to undergo mitochondrial swelling and spontaneous death suggesting that the 
effects of CyP D expression might be cell type-specific
195
. Crompton and colleagues showed 
that a neuronal cell line over expressing CyP-D, was hypersensitive to necrotic cell death 
induced by Ca
2+
 and oxidative stress, but was more resistant to apoptosis induced by nitric 
oxide or staurosporine
228
. 
 
1.8.5 The Role of the MPTP in Reperfusion Injury 
 
The conditions that prevail during ischemia (drop in ATP/ADP, adenine nucleotide depletion 
and the build-up of lactic acid, and drop in intracellular pH) are exactly those that favour 
MPTP opening
170
. ATP levels get severely compromised and calcium accumulates inside the 
cell. Upon reperfusion, this Ca2+ enters the re-energised mitochondria, and the replenished 
oxygen supply leads to the formation of oxygen free radicals and this sets the scene for pore 
opening.  
Using the ‘Hot-DOG’ (DOG is 2-deoxyglucose) technique, Halestrap’s group have 
confirmed that MPTP opening does not occur during ischemia, but does occur after 
approximately 2 min of reperfusion when the pH has returned to normal
170
. They were also 
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able to demonstrate that a significant proportion of the mitochondria that do open initially 
during the reperfusion period, do subsequently close again, and that the recovery of the heart 
correlates best with the extent of this closure
151
. 
 
1.8.5.1.1 Inhibition of the MPTP protects hearts against ischemia reperfusion injury 
The following strategies can be used to inhibit MPTP opening and there by protecting the 
heart against ischemia-reperfusion injury. 
 
1.8.5.1.2 Targeting CyP-D 
In 1991, Nazareth et al demonstrated that CsA could protect isolated cardiac myocytes from 
reoxygenation injury
127
. They demonstrated that cyclosporine-A at a concentration of 0.2 
µmol/l protected the cell against necrotic cell death (assessed by Trypan-blue exclusion and 
LDH release). They showed that the best protective effect could be achieved at 
concentrations of CsA between 0.2-0.4 µmol/l
127
. Subsequently Griffiths and co-workers 
showed protection from reperfusion injury in the Langendorff-perfused heart
130
. These 
findings were confirmed by our group (reduction in the infarct size of hearts subjected to 
ischemia - reperfusion injury with CsA added only at reperfusion) and others using both global 
and regional models of ischemia and reperfusion using enzyme release, infarct size and 
haemodynamic function as end points
68,229
. Furthermore, genetic ablation of CyP-D has been 
demonstrated to protect against ischemia reperfusion injury of the heart
195,197
 and brain
230
 with 
CyP-D knockout mice showing a substantial decrease in infarct size. Thus targeting the 
MPTP has proven potential as a pharmacological target for the reduction of reperfusion injury 
following stroke, coronary thrombosis and heart surgery. However, CsA also inhibits 
calcineurin, which is a calcium-sensitive protein phosphatase, by binding to cytosolic 
cyclophilin-A. This has direct effects on heart function
231
 and also undesirable 
immunosuppressive activity
232
. However, protection by CsA against MPTP opening has been 
reported in human clinical trials and this confirmed reduced infarct size following CsA 
treatment of patients undergoing PCI treatment following a coronary thrombosis
135
. 
To overcome the issue of CsA, SfA can be used which are inactive against 
calcineurin but inhibit MPTP opening and are as effective as CsA even when given at the time 
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of reperfusion
139,143,233,234
. Our group have shown that CsA and SfA can reduce the infarct 
size of hearts when a coronary artery is occluded and then re-opened to mimic the clinical 
treatment of a coronary thrombosis
68,229
. 
  
1.8.5.1.3 Targeting other components of the MPTP and using other strategies 
Targeting another component of the MPTP would be an attractive strategy for 
cardioprotection as MPTP opening may not be totally dependent on CyP-D.  When CyP-D is 
ablated genetically or when fully inhibited with CsA, it has been shown that the permeability 
transition of MPTP can be induced with a higher calcium load or oxidative stress
159,196
. The 
MPTP can be inhibited by targeting the ANT with BKA and this can protect cells from MPTP-
induced cell death in some systems
146,210
. As ANT is vital for the generation of cytosolic ATP 
via oxidative phosphorylation to energise the contractile cycle, this form of cardioprotection is 
not appropriate. 
Popofol can directly inhibit MPTP opening in isolated mitochondri
235
 by scavenging 
free radicals. Javadov et al, using the “Hot-DOG” technique, has demonstrated the inhibition 
of the MPTP by propofol in the intact heart
152
 and in vivo pig model of cardiopulmonary 
bypass with warm blood cardioplegia
157
. Other anaesthetic agents such as isoflurane and 
desflurane have also been shown to offer protection and are associated with less ROS 
formation and calcium overload
236,237
.  
Inhibition of the Na
+
/H
+
 exchanger with amiloride derivatives (cariporide) protects the 
heart from reperfusion injury, by preventing sodium and therefore calcium overload during 
ischemia and maintaining low pH during reperfusion
238,239
. 
Pyruvate, free radical scavenger, also maintains a low intracellular pH and is an 
excellent respiratory substrate to replenish ATP during reperfusion. Direct measurement with 
the “Hot-DOG” technique has confirmed that pyruvate not only reduces MPTP opening at 
reperfusion but closes those pores that were open initially
151
.  
Verapamil and ruthenium red can protect the hearts from reperfusion injury by 
reducing cytosolic and mitochondrial calcium overload
240
. 
 
 
Selvaraj Shanmuganathan Chapter 1: Introduction 
48 
1.8.5.2 Inhibiting MPTP Opening During Ischemia-Reperfusion: the pH Paradox 
The rapid restoration of physiologic pH during myocardial reperfusion after ischemic episode 
contributes to lethal reperfusion injury. This phenomenon is termed the pH paradox
241
. 
Studies In neonatal rat cardiomyocytes have shown that reoxygenation with acidic buffer is 
cardioprotective
242
 and this effect may be mediated by the inhibition of MPTP opening
103
.  
 
1.8.5.3 The MPTP - a target for preconditioning and postconditioning 
 
Finding of IPC by Reimer and Jennings in 1986, has generated a huge research effort to 
elucidate the signal transduction pathways. Current proposal is that the IPC stimulus 
generates autocoids such as adenosine, bradykinin, and opioids, which in turn activate their 
specific G-protein coupled receptors (GPCR) on the cardiomyocyte plasma membrane. A 
complex network of intracellular signalling pathways are recruited many of which converge on 
the mitochondria. This results in the production of mitochondrial reactive oxygen species 
(ROS) activating PKC, Akt and Erk1/2 which convey the cardioprotective signal and the 
‘memory-effect’ of IPC to the unidentified end effector
95,243
.  
Our group demonstrated for the first time that IPC elicited its cardioprotective effect 
by targeting and inhibiting the opening of the MPTP using diazoxide, a purported opener of 
the ATP-sensitive mitochondrial potassium (mitoKATP) channel in adult rat cardiac 
mitochondria
229
.   
Subsequent to its original description in 2003 by Vinten-Johansen’s group
53
 our 
research group and others have provided evidence that IPost is able to activate cell-surface 
receptors such as adenosine, bradykinin and opioids, which then recruit signal transduction 
pathways such as the PI3KAkt, MEK1/2-Erk1/2, cGMP-PKG kinase cascades, which are 
known to terminate on the mitochondria. Ovize’s research group
244
 were able to link IPost with 
the inhibition of MPTP opening using rabbit hearts.  
Several mechanisms have been proposed through which IPC and Ipost inhibits the opening of 
the MPTP at the time of myocardial reperfusion but the actual mechanism is currently 
unresolved. 
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1.9 Summary and Main Objectives of the Thesis 
 
Mitochondrial permeability transition pore opening occurs just after reperfusion under 
pathological conditions such as ischemia-reperfusion injury, where conditions’ predisposing 
for MPTP opening prevails. These include a high mitochondrial [Ca
2+
] and [Pi], ATP depletion 
and oxidative stress. Opening of the MPTP disrupts normal mitochondrial function and 
depletion of energy sources. Hence opening of MPTP is a critical determinant of cell death - 
both apoptotic and necrotic cell death. Therefore, inhibiting MPTP opening during ischemia-
reperfusion injury offers a powerful target for protecting the heart against the reperfusion 
injury. 
 The main aim of this thesis is to demonstrate that MPTP opening does occur at 
reperfusion in human cardiomyocytes and that inhibiting the MPTP opening occurring at the 
time of reperfusion, following a lethal period of ischemia, is an important mechanism for 
cardio-protection in humans, by applying agents at the time of reperfusion.  
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Chapter Two 
 
 
 HYPOTHESIS 
 
Overall hypothesis: 
The mitochondrial permeability transition pore (MPTP) is a target for cardioprotection 
in the human heart 
Aim and objectives: 
1. To determine whether pharmacologically inhibiting MPTP opening at the onset of 
myocardial reperfusion / reoxygenation improves recovery in contractile function 
in human atrial muscle following a period of sustained simulated ischemia. 
2. To determine whether pharmacologically inhibiting MPTP opening at the onset of 
myocardial reoxygenation improves the survival of human atrial cardiomyocytes 
subjected to a period of sustained simulated ischemia. 
3. To demonstrate that MPTP opening occurs in human atrial cardiomyocytes 
subjected to oxidative stress, and that MPTP opening can be inhibited by known 
pharmacological MPTP inhibitors. 
 
In Chapter 4, we examine the effect of pharmacologically inhibiting MPTP opening with known 
inhibitors during the first few minutes of post-ischemic reperfusion (the time-period when 
MPTP opening has been demonstrated to occur) in Human atrial trabeculae and its 
contractile functional recovery. In Chapter 5 and 6, we examine the effects of 
pharmacologically inhibiting MPTP opening by known MPTP inhibitors at the onset of 
reperfusion, on isolated Human myocardial cellular viability and also on the percentage of 
apoptosis and necrosis, in a setting of hypoxia and reoxygenation model. In chapter 7, we 
examine the opening of MPTP secondary to oxidative stress and the direct inhibitory effect 
(delayed opening of MPTP) on the opening of MPTP by the known pharmacological MPTP 
inhibitors, by applying solely at reperfusion, in an isolated Human myocyte using oxidative 
stress model. 
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Chapter Three: GENERAL METHODS 
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3.1 Patients 
 
All the experiments were performed on the tissues harvested from the human right atrial 
appendage. Specimens of human right atrial appendages were obtained from the right atrial 
venous cannulation site at the time of cardiac bypass operation from patients, at the Heart 
hospital, London, undergoing either elective coronary artery bypass graft surgery or elective 
aortic valve replacement, just before they went onto cardio-pulmonary bypass. The patients 
either had coronary artery disease or stenotic disease of the aortic valve with good left 
ventricular function.  
The procedure was explained in detail to all the patients along with the information 
sheet and was given enough time to read, understand and ask questions about the same. 
They were compos mentis while signing the form and were in full agreement for providing 
their right atrial sample for the present study. Prior ethical approval had been obtained from 
the Middlesex Hospital Clinical Investigations panel (00/0275). 
 
3.2 Exclusion criteria 
 
The exclusion criteria were: Patients with 
 Arrhythmias 
 Poor left or right ventricular function 
 Age ≥ 80 years 
 Recent myocardial infarction (within two weeks) 
 Emergency surgery 
 Unstable angina 
 Bacterial endocarditis  
 Patients with anti-arrhythmic drugs, oral hypoglycaemics and Insulin 
 Combined cardiac surgical procedures 
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3.3 Preparation of Adult Human right atrial trabeculae 
 
3.3.1 Isolation of Trabeculae 
 
The advantages of isolated human right atrial muscle (trabecula) preparations are: 
(1) Avoiding the problems of collateral circulation experienced with in-vivo models 
(2) The confounding effects of alterations in pre-load and after-load 
(3)  The measurement of contractile function in the whole heart during simulated ischemia 
and reperfusion is complicated by alterations in the geometry of the cavity associated 
with ischemic contracture, tissue oedema and the effects of changes in coronary 
perfusion pressure 
(4) Free from neuro-humoral effects 
(5) It was available and because sampling was part of the routine cardiac procedure. 
(6) The specimens make stable preparations and are generally disease free. 
 
The disadvantages of isolated human right atrial muscle (trabecula) preparations  
This does not truly represent the ventricular muscle and hence translation into clinical 
scenario is not strictly representative.  
There are several clinical studies suggesting that preconditioning occurs in humans,
28,34,36,245-
247
 but the early direct evidence comes from in vitro studies. Ikonomidis et al
19
 used human 
ventricular cardiomyocyte cell cultures and showed that these isolated myocytes could be 
protected against a 90-minute period of SI by a preconditioning protocol. Our department
18
 
were able to show that human atrial trabeculae can be preconditioned and that had a 
significantly better postischemic recovery of contractile function than non-preconditioned 
trabeculae. There are differences between atrial and ventricular tissue, and results from one 
may not be applicable to the other; however, early experiments in our laboratory (unpublished 
data, 1995) suggest that an identical preconditioning effect can be induced in ventricular 
tissue if a shorter ischemic insult is used (60 minutes instead of 90 minutes).  
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In place of “true” ischemia, the present study used a period of hypoxic superfusion in 
combination with rapid pacing to simulate ischemia, and there is a great deal of evidence in 
animal models of both regional and global hypoxia and in cell culture that hypoxia is as 
effective as ischemia in inducing preconditioning
248-251
. 
We know that preconditioning causes improved recovery of contractile function as 
well as reduced infarct size. Jenkins et al,
252
 measured both infarct volume and functional 
recovery after ischemia and showed that the improved recovery of global left ventricular 
function produced by preconditioning is proportional to a reduction in infarction. Cohen et al
253
 
and Przyklenk et al
76
 were able to correlate improved recovery of systolic shortening with 
reduced infarct size in vivo models of regional ischemia.  
Though there is no direct evidence in atrial tissue that recovery of global function is 
proportional to infarct volume it can be safely assumed that this is likely to be the case. It is 
clear from the evidence that the enhanced recovery of contractile function due to 
preconditioning, following a prolonged period of ischemia, is due to a reduction in infarct size 
and is not due to a reduction in stunning. This model uses a 90-minute period of SI as the 
“ischemic insult,” a period much more likely to lead to cell death than stunning, which is 
induced by shorter periods of 5 to 15 minutes of ischemia suggesting that our model is indeed 
one of preconditioning. However, although unlikely, we cannot entirely exclude the possibility 
that our model involves stunning. 
3.3.1.a Oxygenation of isolated muscle preparation 
In the isolated muscle preparation, delivery of a satisfactory amount of oxygen to all of the 
cells is determined by the rate of oxygen utilisation of the cells, the distance between the 
muscle surface and the core and the oxygen tension of the solution that is surrounding the 
muscle. The core tissue of the isolated muscle preparation may be inadequately oxygenated 
if the diffusion distance for the oxygen is high even in the presence of 95% O2 in the 
superfusate. However the muscle preparations with a small diameter and adequately 
perfused with well oxygenated buffer can remain viable without arterial perfusion. In theory for 
maximum contractility, the muscle specimen must be small enough for the free diffusion of 
substrates (oxygen, glucose and pyruvic acid) and metabolites and that their production can 
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match their diffusion. The diffusion of oxygen to the muscle is the main determinant of their 
contractility
254
.  
There is some dispute among various investigators about what is an appropriate 
maximum diameter of the superfused contracting isolated muscle in pertaining to adequate 
oxygenation. One of the early investigators was A V Hill and he determined the formula from 
biophysical principles to calculate the maximum diameter for adequate oxygenation of an 
isolated muscle preparation
255
. Prasad and Callaghan using the formula calculated that a 
muscle of less than 0.932 mm diameter would be adequately supplied by oxygen by simple 
diffusion in an atmosphere of 95% O2 and 5% CO2 at 37°C and the pacing was at 1 Hz
256
. 
Page and Solomon showed that a superfused cylindrical cat papillary muscle with a diameter 
of 1.12 mm would be adequately oxygenated
257
. The method of superfusing isolated 
specimens of cardiac muscle is well recognised and there are published studies to support 
this technique in human ventricle obtained from explants, where the sample diameter was 1-2 
mm
258,259
. 
The human right atrial trabeculae used in this study ranged between (of diameter 1-2 
mm and length >2 mm). The thinnest of the trabeculae were always used when possible with 
no branches. It was assumed that the muscles were adequately oxygenated as supported by 
the studies above. It might have been possible that the larger muscles have undergone some 
core hypoxia and if that is the case it would equally affect all the groups almost to the same 
degree. The experiments conducted in this study would be still valid as all the atrial 
trabeculae in the groups were similar at baseline. 
 
3.3.1.b Method of isolation of muscle  
This method has been well established and shown to work in our laboratory
260-262
. Specimens 
of right atrial appendages were transported to the laboratory in ice cold oxygenated modified 
Tyrode’s buffer containing (in mM): NaCl 118.5, KCl 4.8, NaHCO3 24.8, KH2PO4 1.2, 
MgSO4.7H2O 1.44, CaCl2.2H2O 1.8, glucose 10.0 and pyruvic acid 10.0. It was ensured that 
the transport time of the specimen from theatre to laboratory was limited to less than 15-20 
minutes. Once in the laboratory the samples were transferred to and well bathed in a Petri 
dish containing oxygenated modified Tyrode’s buffer at room temperature. The specimen was 
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immobilised with pins taking great care and the trabeculae (of diameter 1-2 mm and length ≥ 
2 mm) were harvested with the help of surgical loops (Keeler, 3.5 x magnification). From one 
to three trebaculae were harvested when possible from the each specimen and each of the 
trabeculae were subjected to individual experiments only. The trebeculae were gently 
separated and isolated using fine forceps from the surrounding tissue. The ends of the 
trabeculae were tied with 5/0 silk sutures taking care not to cut the trabeculae. The trabeculae 
were cut from the surrounding tissue i.e. the atrial wall, beyond the silk sutures. They were 
then transferred to an organ bath which is superfused with oxygenated modified Tyrode’s 
solution at 37°C. The trabeculae were suspended horizontally in the organ bath, by tying 
(snared) one end of the trabeculae to a fixed post in the bath and the other end of the 
trabeculae to the force transducer (Gould Statham UCT2, Ohio, USA) that is calibrated before 
each experiment. The organ bath was continuously superfused with oxygenated (95% O2 / 
5% CO2, British Oxygen Company, London, England) modified Tyrode’s buffer and the 
temperature was maintained constant at 37°C using a heat exchanger (Techne Circulator C 
85-A, Cambridge, UK) and was monitored by a thermocouple in the bath. The pH was 
maintained between 7.35 – 7.45; pO2 between 50 – 60 kPa and pCO2 between 4.0 – 6.0 kPa. 
During simulated ischemia (hypoxia) pH was maintained between 7.24 – 7.34 and pO2 <7 
kPa. 
 
3.3.2 Force transducer 
 
The force transducer was attached to a micromanipulator (Prior, Cambridge, England) which 
allowed the force transducer to be manoeuvred with precision. This allowed the manipulation 
of trabeculae on the horizontal position and with precision. The whole setup was mounted on 
a low vibration table.  
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3.3.3 Organ bath 
 
The organ bath was made of non-toxic Perspex and it had a volume of 4 ml and the flow 
through the bath was regulated at about 8 ml / min. The bath was designed with a well at the 
entry point of the buffer to damp the pulsatile flow of the buffer delivered through the pump 
(Watson-Marlow, Cornwall, England). The buffer was constantly removed from the bath 
through pump and so a fresh, constant and steady flow of buffer was ensured to the 
trabeculae. The inflow of buffer was matched with the outflow of the organ bath. At all time 
point it was ensured that the trabeculae were well immersed in the buffer to ensure adequate 
oxygenation. Glass cover slips were used to cover the bath to minimize the gas exchange 
with the atmosphere. Two platinum electrodes were sited by the side of the bath, which 
enabled the trabeculae to be stimulated at required hertz. Once suspended, the trabeculae 
were paced individually by field stimulation at 1 Hz using an isolated stimulator (Digimeter 
DS2, Hertfordshire, UK) triggered by a computerized clock. 
The baths were connected to the water-jacketed glass reservoirs for holding buffers, 
by means of either polythene or silicone tubing. The water-jacketed glass reservoirs were 
connected to the heat exchanger to maintain the temperature at 37°C. The buffers in the 
reservoirs were bubbled constantly with the appropriate gas mixture where necessary and 
were covered with tin foils to minimise heat exchange to the atmosphere and to keep the 
buffers dust free. Three way taps were used to alternate the buffers to the reservoir between 
protocols. The buffers in the reservoir were bubbled with appropriate gas mixtures for a 
minimum of 20 minutes to allow them to be mixed well and this also allowed the buffers to 
reach and maintain the temperature at 37°C. 
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Figure 3-1 A to C: Figure showing (a) stimulator, (b) pump for constant flow of 
buffer and (c) the whole rig including water jacket and the 
computer recording. 
 
 
 
 
Figure 3-2 D and E: Figure showing force transducer and organ bath with electrodes 
on either side mounted on a low vibration table. 
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3.3.4 Stabilisation of the trabeculae 
 
All the trabeculae were suspended in the organ bath and paced at 1 Hz, unstretched, for 30 
minutes. This was the equilibration phase where the trabeculae were allowed to equilibrate 
with the temperature and the buffer. The trabeculae were then gradually stretched in a 
stepwise manner over a period of 15 minutes duration and the resting tension was set at the 
length that produced the maximum degree of force of contraction. The gradual stretch was 
done using the help of the micromanipulator. The stretching process was stopped when there 
was no further increase in the developed force in relation to the length of the trabeculae. 
Once this maximum developed force is achieved the trabeculae were allowed to stabilise for 
further 40-45 minutes (stabilisation phase). The trabeculae were excluded if the maximum 
developed force were <1.0 g. All the groups eventually underwent a period of simulated 
ischemia (SI) and reperfusion which consisted of 90 minutes of hypoxia, when the trabeculae 
were superfused with the substrate free modified Tyrode’s solution and rapid pacing at 3 Hz, 
followed by reperfusion for 120 minutes with normal modified Tyrode’s solution at 1 Hz. A 
one-minute allowance was made for the change over between different buffers in the bath 
and the connecting tubes.  
 
 
Figure 3-3: Figure showing Human right atrial trabecula attached to transducer 
from the pole and perfused in the organ bath. 
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3.3.5 Measurement of force 
 
The trabeculae were suspended, as described above, one end to the fixed pole and the other 
end to the force transducer. The platinum pacing electrodes were positioned on either side of 
the trabeculae in the organ bath and were stimulated at the frequency 1 Hz. The pulse width 
was fixed at 5 ms and the pulse amplitude was set at twice threshold required by each 
individual trabecula for satisfactory pacing (6-8 V).  
The frequency response of the force transducer and its mechanical linkage was 
known to be flat to 50 Hz. The range of the transducer, as per the manufacturer, was ± 30 g 
with a displacement of ± 0.006 mm at the upper ends of this force range. The excitation 
voltage for the force transducer was provided by a DC bridge amplifier (Digimeter, Neurolog 
recorder amplifier NL 107). The output of the force transducer was amplified and recorded 
using PowerLab / 8s (AD Instruments, Australia). The PowerLab recording unit together with 
the chart application program provides a multi-purpose data recording and analysis system 
and was used with a computer.  
The force transducer was calibrated before every single experiment. The chart is 
opened and all the channels were set to zero. The chart was allowed to run while the 
transducer was attached to the known weights (0.5 & 1 g) and calibrated according to the 
known weights. While the baseline is calibrated to zero the upper limit of the weight were 
calibrated to either (0.5 or 1 g) depending on the weight used (mostly 0.5 g). The weights 
were attached to the force transducer with the help of a pulley so that the direction of the pull 
of the weight would be horizontal as the trabeculae would be. The known weights were 
weighed on a calibrated electronic balance, accurate to 5 figures (Mettler AJ50, Leicester, 
England). 
At the end of the reoxygenation period, the contractile function, which is expressed as 
a percentage of the baseline force of contraction, was determined for each atrial trabecula. In 
addition, the width and length of each atrial trabecula was measured and all specimens were 
then weighed. The cross-sectional area was calculated from the measured diameter of the 
atrial trabecula (assuming the trabeculae were cylindrical). 
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3.3.6 Materials 
 
(1) Modified Tyrode’s solution: The modified Tyrode’s solution contains (in mM): 
NaCl 118.5, KCl 4.8, NaHCO3 24.8, KH2PO4 1.2, MgSO4.7H2O 1.44, CaCl2.2H2O 
1.8, glucose 10.0 and pyruvic acid 10.0.  
(2) In the substrate free modified Tyrode’s solution, choline chloride - 7mM was 
substituted for glucose and pyruvic acid to maintain constant osmolarity. All 
reagents were Analar grade (BDH Chemicals, Poole, England) except for pyruvic 
acid (Sigma Chemicals, Poole, England). 
 
3.3.7 Experimental protocols 
 
3.3.7.1 Control group 
Group perfused with either normal buffer or buffer with 0.005% ethanol or 0.01% DMSO 
vehicle control.  
 
3.3.7.2 protocol 
The preconditioning protocol consisted of perfusing the trabeculae with 3 minutes of hypoxic 
substrate-free superfusion of modified Tyrode’s with rapid pacing at 3 Hz followed by 7 
minutes of reperfusion with oxygenated modified Tyrode’s with pacing at 1 Hz. Subsequently 
these trabeculae were subjected to the simulated ischemia and reperfusion protocol. This 
ischemic preconditioning group was included as a positive control to verify that cardio-
protection could be demonstrated in this atrial trabeculae model of SIRI. This hypoxic 
preconditioning protocol has been previous demonstrated in this atrial trabeculae model to 
improve the recovery of myocardial contractile function
18
.   
 
3.3.7.3 Drug groups 
The human atrial trabeculae allocated to the drug groups Cyclosporin (CsA) (0.2 μM) and 
Sanglifehrin (SfA) (1.0 μM) received their corresponding drugs for the first 30 minutes of the 
reperfusion period.  
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1. Cyclosporin-A (CsA, Sigma Chemicals, Poole, Dorset) was dissolved in 50% ethanol 
and added to the buffer such that the final ethanol concentration was 0.005%.  
2. Sanglifehrin-A (SfA, Novartis Pharma AG, Basel) was dissolved in dimethyl 
sulphoxide (DMSO, Sigma Chemicals, Poole, Dorset) and added to the buffer such 
that the final DMSO concentration was 0.01%.  
 
Each trabecula was used for one protocol only and they were randomly assigned to 
the different groups studied. These concentrations of CsA and SfA have been demonstrated 
to inhibit MPTP opening in the isolated perfused rat heart 
68,130,139,229
. 
  
3.4 Isolation of Adult Human Right Atrial Cardiomyocytes 
 
Isolated adult human right atrial cardiomyocytes provide cells, which are free from the neuro-
hormonal influence in an environment, which can be controlled. Human right atrial 
cardiomyocytes were isolated by enzymatic dissociation using protease and collagenase 
digestion, from the right atrial appendages harvested from the patients undergoing elective 
cardiac surgery, just before going on to cardio-pulmonary bypass
263
. Once isolated the right 
atrial samples were immediately transported to the laboratory (in less than 20 minutes) in the 
ice cold oxygenated medium-calcium (MC) solution comprising (in mM): NaCl 120, KCl 5.4, 
MgSO4 5, pyruvate 5, glucose 20, taurine 20, HEPES 10 and Ca
2+
 0.05 (pH 7.4). All buffers 
were made from autoclaved distilled water. In the laboratory, the samples were weighed 
before cardiomyocyte isolation. The right atrial appendage was then freed of any fat and scar 
tissue while still bathed in the ice-cold oxygenated medium-calcium (MC) solution. The right 
atrial appendage was then cut into cubes of 1-2 millimetres using fresh sharp razor blades, 
taking care not to cause shearing action (to prevent crushing the cells) in the oxygenated 
medium calcium (MC) solution at room temperature. The sliced atrial pieces were then 
transferred to 25 ml of Low calcium (LC) solution in a sterile pot and oxygenated with 100% 
O2 while stirring the solution gently for 3 minutes. At the end of 3 minutes the cubes were 
filtered through prolene mesh (300 μm) and were transferred to 25 ml of fresh Low calcium 
solution in a second sterile pot and the above process was repeated a further 3 times in 
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separate sterile pots each time at 37°C (4x3 minutes in total). The filtrate was discarded each 
time. At the end of 12 minutes (3x4 times) the atrial slices were filtered once more through the 
mesh, scraped off and placed into a falcon tube containing 10 ml of the enzyme solution (ES) 
containing protease (Type XXIV, Sigma, USA) and were gently agitated in the agitator / 
shaker in a circular motion at 37°C for 45 minutes, with gentle oxygenation without bubbling. 
Fifteen minutes before the first protease digestion was finished 10 ml of enzyme solution was 
added to the first collagenase in a separate falcon tube and this solution was warmed and 
oxygenated. At the end of 45 minutes of protease digestion the sample was filtered once 
again through the mesh and transferred into 10 ml of enzyme solution containing collagenase 
(Type V, (Clostridium Histolyticum) Sigma, USA) and was again gently agitated in the shaker 
at 37°C for 45 minutes. The sample was filtered once again and the filtrate from the digestion 
was spun in a centrifuge at 1000 rpm for 2 minutes at 37°C. The supernatant was then 
removed carefully by pipetting out the solution and the pellet was re-suspended into 10-12 ml 
of the enzyme solution in a fresh sterile falcon tube and transferred to the incubator. After 
isolation, cell viability was assessed using light microscopy and routinely averaged ~30%. 
 
3.4.1 Materials 
 
(1) Medium-calcium (MC) solution: comprising (in mM): NaCl 120, KCl 5.4, MgSO4 5, 
pyruvate 5, glucose 20, taurine 20, HEPES 10 and Ca
2+
 1-2 M (pH 7.4). 
(2) Enzyme Solution (mM): pH 7.4, Sodium Chloride (NaCl) 120, Potassium Chloride 
(KCl) 5.4, Magnesium Sulphate (MgSO4) 5, Pyruvate 5, Glucose 20, Taurine 20, 
HEPES 10, Calcium Chloride (CaCl2) 35 M. 
(3) Protease 4 U/ml (Type XXIV, (Bacterial) Sigma, USA) 
(4) Collagenase 1 mg/ml (Type V, (Clostridium Histolyticum) Sigma, USA) 
 
3.5 Preparing Human right atrial Cardiomyocytes for Hypoxic chamber 
 
Once the cardiomyocytes were isolated, as described above (section 3.4), they were 
stabilised in oxygenated medium calcium (MC) solution at 37°C in an incubator (CO2 
Incubator, CO28IR, New Brunswick Scientific, USA) in an atmosphere of 95% air/ 5% CO2 for 
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50-60 minutes. Then the cells were transferred on to six well plates and subjected to 
experiments in the hypoxic chamber.  
 
3.5.1 Subjecting cells to hypoxia and reoxygenation  
Cells were subjected to lethal Simulated Ischemia (SI) as follows:  
After stabilising the human atrial cardiomyocytes in the enzyme solution for 50-60 
minutes in the incubation chamber the cells were transferred to the six well plates for the 
experiments. The cell suspension in the enzyme solution (falcon tube) was divided into 2 ml 
solutions in eppendorffs ((a) for the control, (b) for hypoxia and reperfusion alone, (c) for IPC 
group and (d) for hypoxia and drugs). These cells were centrifuged at 1000 rpm for 1-2 
minutes at 37C and re-suspended into the appropriate solutions i.e.  
1. The control group (time control): cells was re-suspended back in the enzyme solution 
into a well of the plates and transferred back to the incubator to be kept at 37C.  
2. Ischemic preconditioning group (IPC): the cells were re-suspended in the modified 
Esumi buffer, pH 6.5 (mM / L): Sodium Chloride (NaCl), 137, Potassium Chloride 
(KCl), 12, Magnesium Chloride (MgCl2) 0.49, Calcium Chloride (CaCl2) 0.9, HEPES 
4, Lactate 20) and transferred into the six well plater and subjected to three minutes 
of hypoxia in the hypoxic chamber followed by seven minutes of reoxygenation (still in 
Esumi buffer) by exposing cells to oxygenation in the incubator followed by hypoxic 
reoxygenation protocol. 
3. Hypoxic group: the cells subjected for hypoxic protocols (control) were re-suspended 
in the modified Esumi buffer and transferred into the wells of the six well plates and 
were subjected to 20 minutes of hypoxia followed by 50 minutes of reoxygenation in 
the enzyme solution.  
4. Drug groups: The drug group were subjected to 20 minutes of hypoxia in the modified 
Esumi buffer like their counterpart hypoxic group in the hypoxic chamber followed by 
50 minutes of reoxygenation in the enzyme solution containing drug (CsA) for the 
entire period of reoxygenation. 
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The cells were then placed in the plates. The cells designated as the time control were placed 
back in the incubator at 37C. The plates for hypoxic protocol (both hypoxic group and drug 
group) were transferred to the hypoxic chamber along with 20 gm of sodium dithionate 
(placed separately in the hypoxic chamber). The hypoxic chamber was closed air tight and 
the temperature was maintained at 37C. The air in the hypoxic chamber was evacuated 
using tubing connected to the cold-water tap (one way) for the first 5 minutes to produce a 
vacuum. For the next fifteen minutes the hypoxic chamber was flushed with argon gas (BOC) 
to replace any oxygenated air left in the chamber and to maintain hypoxia (combined 20 
minutes of hypoxia) with an atmosphere of 0% O2 – 5% CO2
 
balanced with argon. The outlet 
for the argon gas from the hypoxic chamber was connected to an underwater seal to prevent 
air entering into the hypoxic chamber (creating a one way valve). The ischemia was simulated 
by combination of (1) Modified Esumi Buffer, (2) Sodium Dithionate and (3) Hypoxia in the 
chamber. During this hypoxic period the control cells were counted for their baseline viability 
count under light microscope and the result is taken from the average of five fields from the 
single well by an independent observer.  
At the end of the twenty minutes of simulated ischemia the hypoxic chamber was 
opened and the drug Cyclosporin-A (CsA) was added to the cells that are subjected for the 
drug protocol. Now the cells are pippetted out into separate eppendorffs (hypoxic group and 
drug group) including the control and were centrifuged for 1-2 minutes at 1000 rpm. The cells 
from all the groups were re-suspended back in the Enzyme solution (The cells in the drug 
group received the drug CsA along with the Enzyme solution) in separate wells of the 6 well 
plates and were in turn incubated at 37C (reoxygenation).  
The percentages of viable cells were counted under a light microscope at three 
different time points of reperfusion, i.e. at 10, 30 and 50 minutes of the reperfusion period. 
The percentages of viable cells were taken as the average count of five fields for each well at 
any one-time point by an independent observer. The rod shaped cells were counted as the 
viable cells and the rounded ones as dead cells.  
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3.5.2 Experimental protocols for measurement of percentage viability, apoptosis and 
necrosis 
Isolated atrial cardiomyocytes were randomly assigned to the following treatment groups:  
1) Time control group: these cells were left in normoxic conditions at 37.0°C for the 
entire duration of the experimental protocol to act as time controls (positive). 
2) Hypoxic control group: these cells were subjected to 20 minutes of hypoxia followed 
by 30 minutes reoxygenation with either normal buffer / buffer containing the vehicle 
controls (DMSO or 50% ethanol). 
3) CsA group and SfA groups: these cells were subjected to 20 minutes of hypoxia 
followed by 30 minutes of reoxygenation with buffer containing either cyclosporin-A 
(0.2 µM) or sanglifehrin-A (1.0 µM) correspondingly. 
 
 At the end of the 20 minutes re-oxygenation period, the cells were incubated in the dark for 
the final 10 minutes with Annexin-V-Fluos (AV) (20 µM) (Roche, 8 Germany) i.e. the AV was 
added to the cells at the end of 20 minutes of re-oxygenation. Propidium iodide (PI) (3 nM) 
(Sigma) was then added to the cardiomyocytes that was already stained with AV at the end of 
30 minutes of re-oxygenation (10 minutes following the addition of AV) and the samples were 
analyzed immediately using a fluorescent microscope.  
Annexin V (also known as anxA5) has been shown previously to detect the early 
stages of apoptosis by binding to the phosphatidyl serine residues 
264
. This imaging protocol 
is based on the facts that apoptotic cells externalize the negatively charged phospholipid 
phosphatidylserine (PS) and that the human protein annexin A5 (anxA5) binds to PS 
selectively and with a high affinity
265
. Cellular necrosis was determined using PI, which binds 
to the nuclei of cells whose plasma membrane has become permeable
266
.  
For each treatment group, the numbers of rod-shaped, AV stained, and PI stained 
cells were counted in 3 randomly chosen fields by an operator blinded to the treatment, and 
an average value taken. Results were then expressed as a % of the cells counted in the time 
control group (including the solvent group) and were assigned to 3 categories: (1) Live cells 
(AV-negative, PI-negative and rod-shaped); (2) Apoptotic cells (AV-positive, PI-negative); and 
(3) Necrotic cells (PI-positive). 
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3.6 Preparing Human Atrial Cardiomyocytes for Confocal Microscopy 
 
3.6.1 Human atrial cardiomyocyte model for induction and detection of MPTP opening 
Human cardiomyocytes were isolated as above and suspended in the enzyme solution. The 
cells were then seeded onto laminin-coated 25 mm diameter round cover slips placed inside 
the wells of 6 well plates. Once the cover slips were dry, 200 µl of laminin (1mg/ml diluted in 
30 ml of distilled water, Sigma Chemicals, Poole, Dorset) was pipetted onto the centre of the 
cover-slip and left to dry for 60-90 minutes. 500 µl of the cell suspension was then carefully 
placed on the laminin residue in the centre of the cover slip. The cells were left to settle and 
seed onto the cover-slips for 50-60 minutes in an incubator (CO2 Incubator, CO28IR, New 
Brunswick Scientific, USA) at 37C in an atmosphere of 95% air/ 5% CO2. After adequate 
seeding 1 ml of the enzyme solution was added to the cells in each of the wells of the 6 well 
plates. The cells were then subjected for experiments under confocal microscope. All the 
following procedures were conducted in a sterile positive-pressure Microbiological Safety 
Cabinet (Walker Safety Cabinets Ltd, Derbyshire, UK).  
Opening of the MPTP in adult rat myocytes was induced and detected using a well-
characterized cellular model of oxidative stress
201,267-270
. Seeded human atrial 
cardiomyocytes, were incubated with the fluorescent dye, tetramethylrhodamine methyl ester 
(TMRM, 3 µM) for 15 minutes at 37°C, and visualised using confocal fluorescence 
microscopy, as described below. TMRM, a lipophilic cation, accumulates selectively into 
mitochondria according to the mitochondrial membrane potential
271
. Laser illumination of the 
mitochondrial TMRM generates oxidative stress, which is used in this model to induce MPTP 
opening, which is detected by the loss of mitochondrial membrane potential, which in this 
model appears as an increase in TMRM fluorescence intensity. The relatively high 
concentration of TMRM in the mitochondria causes auto-quenching of fluorescence, such that 
the fluorescence signal becomes a non-linear function of dye concentration; therefore, 
mitochondrial depolarisation results in the loss of dye into the cytosol where the signal 
increases
272
.  
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3.6.2 Experimental protocols 
After loading with TMRM, the cells were randomly assigned to the following treatment groups: 
(1) control group: incubation in Enzyme medium with the presence or absence of the DMSO 
and ethanol vehicle controls. 
(2) CsA group: incubation with CsA (0.2 µM) in Enzyme medium for 15 minutes at 37°C. 
(3) SfA group (n=10): incubation with SfA (1.0 µM) in Enzyme medium for 15 minutes 37°C.  
3.6.3 Confocal Microscopy 
All confocal imaging and analysis was conducted in the Mitochondrial Biology Group, the 
department of Physiology, University College London in collaboration with Professor Michael 
Duchen. The 25 mm round cover-slip containing the seeded cardiomyocytes was placed in a 
custom-made chamber with 1 ml of enzyme solution and mounted on the stage of a Zeiss 510 
CLSM confocal microscope equipped with x40 oil immersion, quartz objective lens (NA 1.3). 
For measuring tetramethylrhodamine methyl ester (TMRM) fluorescence, the cells were 
illuminated using the 543 nm emission line of a henna laser. The fluorescence of TMRM was 
collected using a 585 nm long pass filter. For photosensitization experiments, all conditions of 
the confocal imaging system (laser power, confocal pinhole, optical slice and detector 
sensitivity) were identical to ensure comparability between experiments. Images were 
analysed using the Zeiss software (LSM 2.8) and also using Lucida (Kinetic Imaging, Wirral) 
to measure changes in mean and SD of the signals with time.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4: Confocal Microscope with Camera Attached  
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3.7 Statistical Analyses 
  
All results are presented as group means ± standard error of the mean (SEM). For 
comparison between more than two groups, factorial one-way analysis of variance (ANOVA) 
was employed. For analysing data recorded over a period of time, ANOVA for repeated 
measures was employed. Results were considered significant when P≤0.05. All statistical 
analysis was carried out on a Power Macintosh computer, using Statview statistical software 
(Version 4.5, Abacus Concepts Inc.). 
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4.1 Introduction 
 
In section 1.5.5, the role of the mitochondrial permeability transition pore (MPTP) during 
ischemia-reperfusion injury was reviewed. Opening of the MPTP in the first few minutes of 
reperfusion, following an episode of lethal ischemia is a critical determinant of cell death in 
ischemia-reperfusion. The conditions that prevail during the first few minutes of reperfusion 
mediate the opening of the MPTP. These conditions which include a high mitochondrial [Ca
2+
] 
and [Pi], ATP depletion, oxidative stress, correction of the acidic pH, are known inducing 
factors for MPTP opening
7,91-93
. Halestrap’s group in 1995, demonstrated that the MPTP was 
kept firmly closed in the heart under normal physiological conditions but opened upon 
reperfusion following a period of ischemia
143
. Di Lisa’s group
203
 demonstrated the same 
finding using the CsA-sensitive loss of mitochondrial NAD
+
, that occurred during the first few 
minutes of reperfusion to indicate MPTP opening. Marban’s group demonstrated a CsA-
sensitive increase in mitochondrial Ca
2+
 (indicating MPTP opening), occurring at the time of 
reoxygenation, in cardiomyocytes exposed to a sustained period of simulated ischemia.  
Opening of the MPTP results in both apoptotic and necrotic cell death
12,166,209
 and the 
inhibition of its opening during ischemia-reperfusion injury has been demonstrated to confer 
protection in various experimental models. The importance of the MPTP in the necrotic death 
using MPTP inhibitors such as cyclosporin A and sanglifehrin A have been demonstrated in 
the heart, brain and liver
130,139,202,214
. Even if MPTP opening is insufficient to deplete ATP 
levels and cause necrosis, apoptosis may result
12,166,273
. Inhibiting MMP using MPTP 
inhibitors such as CsA or bongkrekic acid have been demonstrated to inhibit apoptotic cell 
death
223,274,275
. 
 Studies in the isolated perfused rat heart have demonstrated that inhibiting MPTP 
opening using CsA restored the ATP/ADP ratio and AMP to pre-ischemic levels and improved 
the recovery of LV function following a prolonged length of ischemia
68,130,229
. Being a 
phosphatase, calcineurin acts to dephosphorylate BAD, thereby enhancing apoptosis. 
Therefore, by inhibiting calcineurin, CsA may mediate cardio-protection via this anti-apoptotic 
mechanism rather than inhibiting MPTP opening.  
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 Recently, the novel immunosuppressant, sanglifehrin-A (SfA), has been shown, to 
also act as a potent inhibitor of MPTP opening
68,139,143,229,233,234
. Studies have examined the 
effect of inhibiting MPTP opening using CsA or SfA at the crucial time of reperfusion alone, 
when the MPTP has been demonstrated to open
68,139,143,229,233,234
. All these studies were 
carried out in various animal and cellular models. 
The method of superfusing isolated specimens of cardiac muscle is well recognised 
and there are published studies to support this technique in human ventricle obtained from 
explants, where the sample diameter was 1-2 mm
258,259
. 
The atrial trabeculae model has been well established and shown to work in our 
laboratory
260-262
. The hypoxic preconditioning protocol has also been previous demonstrated 
in this atrial trabeculae model to improve the recovery of myocardial contractile function
18
.  
The concentrations of CsA and SfA have been demonstrated to inhibit MPTP opening in the 
isolated perfused rat heart
68,130,139,229
. 
However, to our knowledge there has been no study so far which has examined the 
effect of inhibiting MPTP opening using CsA and SfA at the time of reperfusion in the human 
atrial trabeculae model. Therefore the aim of this study was to determine whether 
pharmacologically inhibiting MPTP opening at the time of reperfusion, by using the above 
known MPTP inhibitors, protects the human heart against lethal reperfusion injury, using 
functional recovery of the atrial trabeculae as the measured end-point, in a setting of 
ischemia-reperfusion injury.  
 
4.4 Hypothesis  
 
Opening of the MPTP at the time of reperfusion is a critical determinant of cell death 
and inhibiting its opening is target for cardioprotection in the human heart. 
 
In this study we set out to examine the role of the MPTP in mediating the cell death and in 
turn affecting its functional recovery, induced by lethal reperfusion injury in a human atrial 
trabeculae model. We used cyclosporin-A
68,127,229
 to inhibit the MPTP opening that has been 
demonstrated to occur in the first few minutes of reperfusion. As cyclosporine-A can also 
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inhibit calcineurin, which may be protective by a different mechanism, it was important to use 
a different known inhibitor of MPTP opening that does not inhibit calcineurin. Therefore, we 
also investigated the effect of the newly described MPTP inhibitor, sanglifehrin-A, which does 
not inhibit calcineurin
139,143,233,234
. We administered these agents only at the time of 
reperfusion in order to demonstrate that the opening of the MPTP is an important mediator of 
lethal reperfusion injury, which in turn would affect the functional recovery. We used samples 
from the right atrium of humans undergoing cardio-pulmonary bypass, in a setting of 
ischemia-reperfusion / hypoxia-reoxygenation model to demonstrate the effect of known 
pharmacological inhibitors on MPTP opening at the time of reperfusion.  
 
4.3 Aim  
 
To determine whether pharmacologically inhibiting MPTP opening at the onset of 
myocardial reperfusion improves recovery in contractile function in human atrial 
muscle following a period of sustained simulated ischemia.  
 
4.3.1 Materials 
1. Cyclosporin-A: (Sigma Chemicals, Poole, Dorset) was dissolved in 50% ethanol and 
added to the modified Tyrode’s buffer such that the final ethanol concentration was 
less than 0.005%.  
2. Sanglifehrin-A: (Novartis Pharma AG, Basel) was dissolved in dimethyl sulphoxide 
(DMSO, Sigma Chemicals, Poole, Dorset) and added to the modified Tyrode’s buffer 
such that the final DMSO concentration was 0.01%. All other reagents were of 
standard analytical grade.  
3. Modified Tyrode’s solution: The modified Tyrode’s solution contains (in mM): NaCl 
118.5, KCl 4.8, NaHCO3 24.8, KH2PO4 1.2, MgSO4.7H2O 1.44, CaCl2.2H2O 1.8, 
glucose 10.0 and pyruvic acid 10.0. In the substrate free modified Tyrode’s solution, 
choline chloride - 7mM was substituted for glucose and pyruvic acid to maintain 
constant osmolarity. All reagents were Analar grade (BDH Chemicals, Poole, 
England) except for pyruvic acid (Sigma Chemicals, Poole, England). 
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4.3.2 Isolated Human right Atrial Trabeculae model 
 
The human right atrial samples were taken from patients undergoing routine bypass 
operations and the trabeculae isolated from them were mounted on a perfused bath 
apparatus and subjected to 90 minutes of simulated ischemia (hypoxia) followed by 120 
minutes of reperfusion (reoxygenation) (see section 3.3.1). At the end of the reperfusion 
period, the baseline functional recovery was determined (see section 3.3.4 and 3.3.5).  
 
4.3.3 Experimental protocols 
 
All the trabeculae were suspended in the organ bath and paced at 1 Hz, unstretched, for 30 
minutes. The trabeculae were then gradually stretched in a stepwise manner over a period of 
15 minutes duration until resting tension was set at the length that produced the maximum 
degree of force of contraction. Once this maximum developed force is achieved the 
trabeculae were allowed to stabilise fore 45 minutes (stabilisation phase). All the groups 
eventually underwent a period of simulated ischemia (SI) and reperfusion which consisted of 
90 minutes of hypoxia, when the trabeculae were superfused with the hypoxic substrate free 
modified Tyrode’s solution and rapid pacing at 3 Hz, followed by reperfusion for 120 minutes 
with oxygenated modified Tyrode’s solution at 1 Hz. Each trabecula was used for one protocol 
only and they were randomly assigned to the different groups studied.  
The experiment protocols for the functional recovery of the trabeculae studies are 
presented in Figure 4.1. The trabeculae were randomly assigned to one of the following 
treatment groups:  
(1) Control Group: trabeculae were perfused with the vehicles 0.005% ethanol (n=3), or 
0.01% DMSO (n=3) or Modified Tyrode’s buffer alone (n=6) during the first 30 
minutes of reperfusion following the simulated period of ischemia. 
(2) Ischemic Preconditioning Group (IPC): trabeculae (n=6) were subjected to the 
preconditioning protocol which consisted of 3 minutes of hypoxic substrate free 
superfusion of modified Tyrode’s buffer with rapid pacing at 3 Hz followed by 7 
minutes of reperfusion with oxygenated modified Tyrode’s with 1 Hz pacing. 
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Subsequently these trabeculae were subjected to the simulated ischemia and 
reperfusion protocol. This group that includes solvents group (Ethanol / DMSO) was 
used as a positive control for the further experiments. 
(3) CsA-treatment: trabeculae (n=6) were perfused with cyclosporin-A (0.2 mol/l) 
during the first 15 minutes of reperfusion. This concentration of CsA has been 
demonstrated to provided the most potent inhibition of MPTP opening in adult rat 
myocytes
130
. 
(4) SfA-treatment: trabeculae (n=6) were perfused with sanglifehrin-A (1.0 mol/l) during 
the first 15 minutes of reperfusion. This concentration of SfA has been demonstrated 
to give the most potent inhibition of MPTP opening
139
. 
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cyclosporin-A, SfA-sanglifehrin-A. (Time control includes solvent group). 
 
4.4 Results 
4.4.1 Exclusions 
Samples were obtained from 31 patients with stable ischemic heart disease (24 men and 7 
women; age range 48-76; mean age 67 years). If two or three suitable trabeculae could be 
isolated from a single atrial appendage then each atrial trabeculae was allocated to one of 
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three experiment groups (three sets of apparatus were used simultaneously). 10 atrial 
trabeculae were excluded because of poor baseline contractile function.  
4.4.2 Experimental Data and Results 
 
Baseline characters such as the cross sectional area and length and weight (mass) of the 
trabeculae were similar in all the experimental groups (see table 4.1).  
The percentage contraction of the trabeculae from their baseline at regular time 
intervals throughout the simulated hypoxia and reoxygenation is shown in the tables (see 
tables 4.2, 4.3) (Figure 4.2). The percentage contractile function were quite similar in all the 
groups at the end of the simulated ischemia (see table 4.2). During the reoxygenation period 
the recovery of the trabeculae in the IPC and in the drug groups were significantly (P<0.001) 
higher compared to the control group, even from the very beginning of the reoxygenation 
period of 15 minutes (see table 4.3). This recovery in the force of contraction of the trabeculae 
was maintained throughout the reoxygenation period up until 120 minutes in the IPC and drug 
groups (figure 4.2). Figure 4.3 shows the functional recovery of the human atrial trabeculae at 
the end of the experiment (30 minutes of hypoxia and 120 minutes of reperfusion). The 
functional recovery of the trabeculae in the IPC (48.7±4.3) and the drug groups (CsA = 
48.7±2.2 and SfA = 46.4±2.2) (see table 4.3) were significantly (*P<0.001) higher than the 
control group (29.4±1.9).  
 
 
 
Groups 
 
Length (mm) 
 
Mass (mg) 
 
Area (mm
2
) 
 
Developed force 
(g) 
 
 
1. Control 
 
4.2±0.5 
 
0.9±0.0 
 
0.6±0.1 
 
1.4±0.2 
 
2. IPC 
 
3.7±0.2 
 
0.8±0.1 
 
0.6±0.1 
 
1.2±0.2 
 
3. CsA  
 
3.3±0.3 
 
0.9±0.1 
 
0.5±0.1 
 
1.5±0.2 
 
4. SfA 
 
3.4±0.3 
 
0.8±0.0 
 
0.5±0.0 
 
1.4±0.1 
Values are mean ± SEM. 
 
Table 4.1: Physical Characteristics of Human Atrial Trabeculae in Study Groups 
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Values are mean ± SEM.  
 
Table 4.2: Haemodynamic Data of Human Atrial Trabeculae in Study Groups 
during Ischemia (% of baseline contraction) 
 
 
 
 
 
REOXYGENATION 
(minutes) 
 
 
Control 
 
IPC 
 
CsA 
 
SfA 
 
15  min 
 
17.9±3.6 
 
32.4±7.2* 
 
40.2±8.6* 
 
34.4±9.2* 
 
 
30  min 
 
17.6±3.8 
 
 
38.6±6.8* 
 
 
35.9±6.6* 
 
 
35.9±4.0* 
 
 
45  min 
 
22.5±3.6 
 
 
46.7±7.6* 
 
 
40.1±4.5* 
 
 
38.5±4.3* 
 
 
60  min 
 
30.3±2.7 
 
 
50.9±7.3* 
 
 
44.6±3.5* 
 
 
42.2±4.1* 
 
 
75  min 
 
24.6±2.3 
 
 
51.6±6.6* 
 
 
46.3±3.2* 
 
 
43.6±4.1* 
 
 
90  min 
 
28.8±2.6 
 
 
50.2±5.6* 
 
 
47.5±3.0* 
 
 
42.9±3.4* 
 
 
105 min 
 
29.9±2.4 
 
 
50.2±4.9* 
 
 
47.5±2.7* 
 
 
44.3±3.0* 
 
 
120 min 
 
29.4±1.9 
 
48.7±4.3* 
 
 
48.7±2.2* 
 
 
46.4±2.2* 
 
Values are mean ± SEM. 
 
Table 4.3: Contractile functional recovery of Human Atrial Trabeculae in Study 
Groups during Reperfusion / Reoxygenation (% of baseline contraction) 
 
Hypoxia  
(minutes) 
 
 
Control 
 
IPC 
 
CsA 
 
SfA 
 
30 min 12.2±2.5 
 
11.9±3.1 
 
9.6±2.2 
 
7.5±1.6 
 
 
60 min 9.1±3.4 
 
6.8±0.9 
 
7.9±2.1 
 
5.2±1.3 
 
 
90 min 
 
3.7±0.7 
 
 
4.4±0.6 
 
4.5±1.3 
 
 
4.7±1.4 
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Figure 4.2:  Inhibiting MPTP opening at the time of reperfusion improves the 
functional recovery of the human right atrial trabeculae and protects 
against lethal reperfusion injury.  
The functional recovery of the trabeculae in the IPC, CSA and SFA groups 
showed significant functional recovery compared to the control group from 
the very beginning of the reoxygenation period and was maintained 
throughout. *P<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3  Inhibiting MPTP opening at the time of reperfusion protects the heart 
against lethal reperfusion injury and improves functional recovery.  
Pharmacologically inhibiting MPTP opening for the first 30 minutes of 
reperfusion using either cyclosporin-A (CsA) or sanglifehrin-A (SfA) improved 
the functional recovery of the trabeculae after 120 min reperfusion and so is 
cardioprotective. *P<0.001. 
Contractile functional recovery of atrial trabeculae 
0 
10 
20 
30 
40 
50 
60 
70 
minutes 
Hypoxia(90 ms) and Reoxygenation (120 ms) 
%  
Control 
IPC 
CsA 
SfA 
* * 
* 
* * * * * 
Control IPC CsA SfA 
0
10
20
30
40
50
60
%
 o
f 
b
a
s
e
li
n
e
 
* * * 
210 minutes 
Selvaraj Shanmuganathan    Chapter 4: Trabeculae functional recovery model  
79 
4.5   Discussion 
In this part of the study we demonstrated that pharmacologically inhibiting MPTP opening for 
the first 30 minutes of reperfusion, following a lethal period of ischemia, using either 
cyclosporin-A (CsA) or sanglifehrin-A (SfA), protected the heart against lethal reperfusion 
injury, as evidenced by a increase in the recovery of the percentage contraction of the 
trabeculae from their baseline function. This is evident from the early recovery of the 
myocardial function even at 15 minutes of the beginning of the reperfusion period. The IPC 
group was used a positive control to show the effect of inhibition of MPTP with CsA and SfA. 
Importantly, the known MPTP inhibitors were only given at the time of reperfusion, to target 
the time period when MPTP opening has been demonstrated to occur
12,143,166,170
. Our 
experiments have shown that the opening of MPTP occurs during reperfusion and that by 
inhibiting their opening we could prevent the lethal effects of reperfusion injury and hence 
MPTP is a target for cardioprotection in human heart.   
 The improvement in the functional recovery induced by CsA at reperfusion was not 
due to its effect on calcineurin but was most likely due to its suppression of MPTP opening. In 
support of this, we also demonstrated protection against lethal reperfusion injury using 
sanglifehrin-A, which does not inhibit calcineurin
143
. Therefore, providing these agents were 
administered in a timely manner, we were able to inhibit MPTP opening despite the presence 
of the MPTP-inducing factors that prevail in the first few minutes of reperfusion. 
 
4.6   Conclusion 
 
In conclusion, we have demonstrated that pharmacologically inhibiting MPTP opening during 
early reperfusion protects the human heart against lethal reperfusion injury and improve its 
functional recovery. From the results of this part of the study, it appears that the opening of 
the MPTP at the time of reperfusion mediates lethal reperfusion injury. We used the known 
pharmacological MPTP inhibitors (CsA and SfA) with known concentrations that were proven 
to inhibit MPTP in various animal studies
68,130,139,202,214,229
. The early reperfusion therefore 
represent a ‘window of opportunity’ for interventions directed to attenuating lethal reperfusion 
injury, via inhibition of MPTP opening.  
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5.1 Introduction 
 
Next we go on to show the effect, of inhibiting the mitochondrial permeability transition pore at 
reperfusion using the above known inhibitor Cyclosporin-A (CsA), on the viability of the 
human atrial cardiomyocytes after subjecting them to a period of SIRI.  
Opening of the MPTP in the first few minutes of reperfusion, following an episode of 
lethal ischemia is a critical determinant of cell death in ischemia-reperfusion. Opening of the 
MPTP results in both apoptotic and necrotic cell death
12,166,170,209
 and hence affects the 
viability of cells. Inhibition of MPTP opening during ischemia-reperfusion injury has been 
demonstrated to confer protection in various experimental models
130,139,202,214,223,274,275
. In 
myocytes subjected to lethal hypoxia-reoxygenation, the presence of CsA improved cell 
viabilit
68,127,229
. 
However, to our knowledge there has been no study so far to examine the effect of 
inhibiting MPTP opening using CsA at the time of reperfusion in human cardiomyocyte model.   
 
Therefore the aim of this study was:  
(1) To determine whether pharmacologically inhibiting MPTP opening at the time of 
reperfusion, protects the human heart against lethal reperfusion injury, using cell 
viability as the measured end-point, in a setting of ischemia-reperfusion injury.  
(2) To characterise the model of ischemia / reperfusion in the human cardiomyocytes 
using hypoxic chamber to induce simulated ischemia / hypoxia simultaneously. 
 
5.2 Hypothesis  
   
Opening of the MPTP at the time of reperfusion is a critical determinant of cell death and 
inhibiting its opening is a target for cardioprotection in the human heart 
 
In this study we set out to examine the role of the MPTP in mediating the cell death induced 
by lethal reperfusion injury in a human model. The aim of this study was also to characterise 
the model of ischemia / reperfusion (hypoxia / re-oxygenation) in the human cardiomyocyte 
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using the hypoxic chamber for simulating hypoxia / ischemia at the same time. We used 
cyclosporin-A (the archetypal MPTP inhibitor)
143
 to inhibit the MPTP opening that has been 
demonstrated to occur in the first few minutes of reperfusion
202,203
. Cyclosporine-A can also 
inhibit calcineurin, which may be protective by a different mechanism. We only tested 
Cyclosporin-A to inhibit MPTP at reperfusion in this experiment as we were trying to establish 
the model of ischemia / reperfusion in human cardiomyocytes using hypoxic chamber to 
induce simulated ischemia, at the same time as we were trying our above hypothesis. We 
administered CsA only at the time of reperfusion in order to demonstrate that the opening of 
the MPTP is an important mediator of lethal reperfusion injury. We used samples from the 
right atrium of humans undergoing cardio-pulmonary bypass, in a setting of ischemia-
reperfusion / hypoxia-reoxygenation model to demonstrate the effect of known 
pharmacological inhibitor (CsA) on MPTP opening at the time of reperfusion. We used the 
human cardiomyocyte model to demonstrate that inhibiting the opening of MPTP at 
reperfusion can be cardio-protective and increase the percentage of cellular viability.   
 
5.3 Aim 
 
To determine whether pharmacologically inhibiting MPTP opening at the onset of 
myocardial reoxygenation improves the survival of human atrial cardiomyocytes 
subjected to a period of sustained simulated ischemia. 
 
5.3.1 Materials 
 
1. Cyclosporin-A: (Sigma Chemicals, Poole, Dorset) were dissolved in 50% ethanol and 
added to the enzyme solution such that the final ethanol concentration was less than 
0.005%. All other reagents were of standard analytical grade. 
2. Medium / Low-calcium (MC) solution: comprising (in mM): NaCl 120, KCl 5.4, MgSO4 
5, pyruvate 5, glucose 20, taurine 20, HEPES 10 and Ca
2+
 1-2 M (pH 7.4). 
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3. Enzyme Solution (mM): pH 7.4, Sodium Chloride (NaCl) 120, Potassium Chloride 
(KCl) 5.4, Magnesium Sulphate (MgSO4) 5, Pyruvate 5, Glucose 20, Taurine 20, 
HEPES 10, Calcium Chloride (CaCl2) 35 M.   
4. Modified Esumi Buffer (mM): pH 6.5, Sodium Chloride (NaCl), 137, Pottasium 
Chloride (KCl), 12, Magnesium Chloride (MgCl2) 0.49, Calcium Chloride (CaCl2) 0.9, 
HEPES 4, Lactate 20 
5. Sodium Dithionite (0.5 mM) 
 
5.3.2 Isolated Human right Atrial cardiomyocyte model 
The human right atrial samples were taken from patients undergoing bypass operations and 
the isolated cardiomyocytes (section 3.4 and 3.5) were then placed on 6 well plates and 
subjected to 20 minutes of simulated ischemia (hypoxia) followed by 50 minutes of 
reperfusion (reoxygenation) (see section 3.5). During the reperfusion period, at three different 
time points (10, 30 and 50 minutes of reperfusion), the percentages of viable cells were 
determined.  
 
5.3.2a Hypoxic Preconditioning Protocol  
Cells were incubated in a hypoxic (PaO2 < 3 KPa) chamber (Heraeus, Kendro Laboratory 
Products, Germany) for 3 minutes at 37C in anoxic buffer with an intervening 7 minutes 
reoxygenation prior to undergoing hypoxic reoxygenation protocol. The anoxic buffer is a 
modification of that described by Esumi and colleagues
276
. The cells were in the modified 
Esumi buffer during the reperfusion period of seven minutes before the ischemia / reperfusion 
protocol, as changing the buffer for the seven minute period of reperfusion would have an 
additional variable to the cells i.e. centrifuging the cells for two more times and this was 
avoided. 
 
5.3.2b  Establishing the model of human atrial cell viability using hypoxic chamber 
After stabilising the human atrial cardiomyocytes in the enzyme solution for 50-60 minutes in 
the incubation chamber the cells were transferred to the six well plates for the experiments. 
The cell suspension in the enzyme solution (falcon tube) was divided into 2 ml solutions into 
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eppendorffs ((1) for the control, (2) for hypoxia and reperfusion alone, (3) for IPC group and 
(4) for hypoxia and CsA + reperfusion). These cells were centrifuged at 1000 rpm for 1-2 
minutes and re-suspended into the appropriate solutions i.e.  
1) The control group: cells was re-suspended back in the enzyme solution into a well of 
the plates and transferred back to the incubator to be kept at 37C.  
2) Ischemic preconditioning group: the cells were re-suspended in the modified Esumi 
buffer and transferred into the six well plates and subjected to three minutes of 
hypoxia in the hypoxic chamber followed by seven minutes of reoxygenation (partial – 
as still in Esumi buffer) by exposing them to oxygenation in the incubator followed by 
hypoxic reoxygenation protocol. 
3) Hypoxic group: the cells subjected for hypoxic protocols were re-suspended in the 
modified Esumi Buffer and transferred into the wells of the six well plates. This group 
consists of both the hypoxic group and the drug group as both were subjected for 
hypoxic protocol. 
 
The plates for hypoxic protocol (both hypoxic group and drug group) were transferred to 
the hypoxic chamber along with sodium dithionite (separately in the hypoxic chamber). The 
hypoxic chamber was closed airtight and the temperature was maintained at 37C. The air in 
the hypoxic chamber was evacuated using tubing connected to the cold-water tap (one way) 
for the first 5 minutes to produce a vacuum. For the next fifteen (15 minutes) minutes the 
hypoxic chamber was flushed with argon gas (BOC) to replace any oxygenated air left in the 
chamber and to maintain hypoxia (combined 20 minutes of hypoxia). The outlet for the argon 
gas from the hypoxic chamber was connected to an underwater seal to prevent air entering 
into the hypoxic chamber.  
The ischemia was simulated by combination of (1) Modified Esumi Buffer, (2) Sodium 
Dithionate and (3) Hypoxia in the chamber. During this hypoxic period the control cells were 
counted for their baseline viability count under light microscope and the result was taken from 
the average of five fields from the single well by an independent observer.  
At the end of the twenty minutes (of simulated ischemia the hypoxic chamber was 
opened and the drug Cyclosporin-A (CsA) was added to the cells that were subjected for the 
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drug protocol. The cells were then pippetted out into separate eppendorffs (hypoxic group and 
drug group) including the control and were centrifuged for 1-2 minutes at 1000 rpm. The cells 
from all the groups were re-suspended back in the enzyme solution (The cells in the drug 
group will get the drug CsA along with the enzyme solution) in separate wells of the 6 well 
plates, which were in turn incubated at 37C (reoxygenation).  
Next the percentage of viable cells was counted using a light microscope at three 
different time points of reperfusion, at 10, 30 and 50 minutes of the reperfusion period. The 
percentage of viable cells was taken as the average count of five fields for each well at any 
one-time point by an independent observer. The rod shaped cells were counted as the viable 
cells and the rounded ones as dead.  
 
5.3.3 Experimental Protocols 
 
The experiment protocols for the cellular viability of the atrial cardiomyocyte studies are 
presented in Figure 5.1. 
The cells were assigned to one of the following treatment groups:  
(1) Control Group: cardiomyocytes were stabilised in the enzyme solution perfused with 
the vehicles 0.005% ethanol (n=4), or 0.01% DMSO (n=4) during the whole 
experiment of 70 minutes (equivalent of 20 minutes of simulated hypoxia and 50 
minutes of total reperfusion) This group was used as positive control for the further 
experiments.  
(2) Hypoxic Group: cardiomyocytes (n=7) were subjected to simulated hypoxia for 20 
minutes in the hypoxic chamber in the modified Esumi buffer along with sodium 
dithionate at 37C followed by 50 minutes of total reoxygenation in the enzyme 
solution in the incubator. This group was used as a positive control for the further 
experiments. 
(3) Ischemic Preconditioning Group (IPC): cardiomyocytes (n=6) were subjected to 
the preconditioning protocol which consisted of 3 minutes of simulated hypoxia in the 
modified Esumi buffer followed by 7 minutes of reperfusion (oxygenated at 37C in 
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the incubator but still in the modified Esumi buffer). Subsequently these cells were 
subjected to the simulated hypoxia and reoxygenation protocol. 
(4) CsA-treatment: cardiomyocytes (n=6) were perfused with cyclosporin-A (0.2 mol/l) 
during the entire period of reperfusion. This concentration of CsA has been 
demonstrated to inhibit MPTP opening in the isolated perfused rat heart. 
 
 
 
Figure 5.1: Experimental Protocols for Investigating the Effect of 
pharmacologically Inhibiting MPTP Opening on Viability of Human Right 
Atrial Cardiomyocytes. CsA-cyclosporin-A. 
 
 
 
 
5.4 Results  
5.4.1 Exclusions 
Samples were obtained from 29 patients with stable heart disease (20 men and 9 women; 
age range 48-76; mean age 67 years). When there were good yield of cells, it was possible to 
allocate the cells for the above four groups of experiments. 11 samples were excluded 
because of poor yield or no cells in the digest or dead cells (no live cells) at the beginning of 
the experiment.  
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5.4.2 Experimental Data and Results 
 
The baseline percentage of viable cells from the time control ranged from 20% to 39% and 
the average was 28% (this was taken as 100% at baseline). The percentage of viable cells in 
the groups: hypoxic control, IPC and CsA were significantly lower compared to the time 
control all the way through the reperfusion period. The difference in the percentage of viable 
cells between the groups is evident from the beginning of reperfusion (Positive Control = 
20.1±0.8, Hypoxic control = 11.1±0.9, IPC = 14.6±1.0 and CsA = 15.8±0.7) (see table 5.1). 
The percentage of live cells in the time control shows gradual decline from the baseline count 
to 50 minutes of reperfusion (from 20.1±0.8 to 14.2±1.4) (Figure 5.3). The percentages of 
viable cells were significantly higher in the time control compared to all other groups 
throughout the experiment. This can be explained by the cells in the other groups i.e. 
hypoxic, IPC and CsA groups undergoing stress during centrifuging (twice) and during 
simulated hypoxia / reoxygenation period. The viable cells in the groups IPC (12.3±1.1) and 
CsA (12.6±1.1) (see table 5.1) were significantly (P<0.03) higher in number compared to the 
viable cells in the hypoxic control (8.7±0.9) until 30 minutes of reperfusion Figure 5.2(a-b). At 
50 minutes of reperfusion, though the cells in the groups IPC (8.8±0.6) and CsA (9.5±1.1) 
had more viable cells compared to their hypoxic counterpart (6.7±1.1) (see table 5.1), they 
were not statistically significant Figure 5.2c. 
 
 
Groups 
 
Number 10 min 30 min 50 min 
 
1. Time Control 
8 20.1±0.8** 16.9±1.1** 14.3±1.4** 
 
2. Hypoxic control 
7 11.1±0.9 8.7±0.9 6.7±1.1 
 
3. IPC 
6 14.7±1.0* 12.3±1.1* 8.8±0.6 
 
4. CsA 
6 15.8±0.7* 12.7±1.1* 9.5±1.1 
Values are mean ± SEM.  
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Table 5.1: This table shows the average percentage of viable cells at 10, 30 and 50 
minutes of reperfusion period. IPC – ischemic preconditioning; CsA – 
Cyclosporin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.a:  Graph showing the % of viable cells at 10 minutes of reperfusion. The % 
of viable cells in the IPC and CsA groups were statistically higher than their 
hypoxic control counterpart, *P<0.01; whereas the % of viable cells in the 
time control were statistically higher compared to the other groups, 
**P<0.002. IPC – ischemic preconditioning; CsA – Cyclosporin A. 
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Figure 5.2.b:  Graph showing the % of viable cells at 30 minutes of reperfusion. The % 
of viable cells in the IPC and CsA groups were statistically higher than their 
hypoxic control counterpart, *P<0.03; whereas the % of viable cells in the 
time control were statistically higher compared to the other groups, 
**P<0.0001. IPC – ischemic preconditioning; CsA – Cyclosporin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.c:  Graph showing the % of viable cells at 50 minutes of reperfusion. There 
was no statistical difference in the % of live cells between the hypoxic control, 
IPC and CsA groups. However the % of viable cells in the time control were 
statistically higher compared to the other groups, **P<0.0001. IPC – ischemic 
preconditioning; CsA – Cyclosporin A. 
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Figure 5.3:  This graph shows the % of viable cells at reperfusion between Time 
control, Hypoxic control, IPC and CsA groups. Pharmacologically 
inhibiting MPTP opening at reperfusion using cyclosporin-A (CsA) improved 
the % viability of the myocytes and so is cardioprotective. IPC – ischemic 
preconditioning; CsA – Cyclosporin A. *P<0.03. 
5.4 Discussion 
 
In this part of the study we demonstrated that pharmacologically inhibiting MPTP opening for 
the first 30 minutes of reperfusion, following a lethal period of hypoxia / ischemia, using 
cyclosporin-A (CsA), protected the heart against lethal reperfusion injury, as evidenced by an 
increase in the percentage of live cardiomyocytes. This is evident from the early recovery of 
the myocardial cell viability even at 10 minutes of the beginning of the reoxygenation / 
reperfusion period. The IPC group was used as a positive control to show the effect of 
inhibition of MPTP with CsA. Importantly, the known MPTP inhibitor were only given at the 
time of reoxygenation / reperfusion, to target the time period when MPTP opening has been 
demonstrated to occur
12,166,170
. Our experiments have shown that the opening of MPTP 
occurs during reperfusion and that by inhibiting their opening we could prevent the lethal 
effects of reperfusion injury and hence MPTP is a target for cardioprotection in human heart.   
The cells in the IPC group were left in the Esumi buffer during their reoxygenation 
period for seven minutes following the index hypoxia / ischemic period of three minutes to 
avoid an additional variable (centrifuging X 2) to this cell group from others. This might have 
possibly not provided full oxygenation to the cells during the index reoxygenation / reperfusion 
period of seven minutes. Yet the cells in the IPC group showed a significant percentage of 
viable cells (12.3±1.1) compared to the percentage of viable cells in the hypoxic group 
(8.7±0.9) at the end of 30 minutes of reperfusion period. This suggests that reoxygenation 
was possible for preconditioning the cells though they were in hypoxic buffer (Esumi) for three 
minutes. 
Therefore, providing CsA was administered in a timely manner, we were able to 
inhibit MPTP opening despite the presence of the MPTP-inducing factors that prevail during 
reperfusion. 
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5.6   Conclusion 
 
In conclusion, we have demonstrated that pharmacologically inhibiting MPTP opening during 
reperfusion protects the human heart against lethal reperfusion injury and improve its cellular 
viability. From the results of this part of the study, it appears that the opening of the MPTP at 
the time of reperfusion mediates lethal reperfusion injury leading to necrosis and apoptosis. 
We used the known pharmacological MPTP inhibitor CsA with known concentrations that 
were proven to inhibit MPTP in various animal studies
68,130,139,202,214,229
. The first few minutes 
of reperfusion therefore represent a ‘window of opportunity’ for interventions directed to 
attenuating lethal reperfusion injury, via inhibition of MPTP opening.  
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6.1 Introduction 
 
Next we go on to show the effect, of inhibiting the mitochondrial permeability transition pore at 
reperfusion using the known inhibitors, Cyclosporin-A (CsA) and sanglifehrin-A (SfA), on the 
percentage viability, apoptosis and necrosis of the human atrial cardiomyocytes after 
subjecting them to a period of lethal hypoxia / ischemia. We also aimed to quantify the 
percentage of apoptotic and necrotic cells simultaneously in the same experiments. 
Opening of the MPTP in the first few minutes of reperfusion, following an episode of 
lethal ischemia is a critical determinant of cell death in ischemia-reperfusion. Opening of the 
MPTP results in both apoptotic and necrotic cell death
12,166,170,209
, and the inhibition of its 
(MPTP) opening during ischemia-reperfusion injury has been demonstrated to confer 
protection in various experimental models
68,130,139,202,214,223,229,274,275
. Although cyclosporin-A 
(CsA) is a potent inhibitor of MPTP opening, it also has other actions, which include inhibiting 
the activity of the protein phosphatase, calcineurin and therefore CsA may mediate cardio-
protection via this anti-apoptotic mechanism. The novel immunosuppressant, sanglifehrin-A 
(SfA), has been shown, to also act as a potent inhibitor of MPTP opening
68,139,143,229,233,234
 and 
has been demonstrated to be a more potent inhibitor of MPTP opening than CsA, and in 
addition SfA does not inhibit calcineurin. Studies have examined the effect of inhibiting MPTP 
opening using CsA or SfA at the crucial time of reperfusion alone, when the MPTP has been 
demonstrated to open
68,139,143,229,233,234
. All these studies were carried out in various animal 
and cellular models. 
However, to our knowledge there has been no study so far have examined the effect 
of inhibiting MPTP opening using CsA and SfA at the time of reperfusion in human 
cardiomyocyte model.  Therefore the aim of this study was to determine whether 
pharmacologically inhibiting MPTP opening at the time of reperfusion, protects the human 
heart against lethal reperfusion injury, using percentage cell viability, apoptosis and necrosis 
as the measured end-points in a setting of hypoxia- reoxygenation injury.  
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6.2 Hypothesis  
   
Opening of the MPTP at the time of reperfusion is a critical determinant of cell death and 
inhibiting its opening is a target for cardioprotection in the human heart. 
 
In this study we set out to examine the role of the MPTP in mediating the cell death induced 
by lethal reperfusion injury in a human model. We used cyclosporin-A and sanglifehrin-A 
(does not inhibit calcineurin) to inhibit the MPTP opening that has been demonstrated to 
occur in the first few minutes of reperfusion. We administered these agents only at the time 
of reperfusion in order to demonstrate that the opening of the MPTP is an important mediator 
of lethal reperfusion injury. We used samples from the right atrium of humans undergoing 
cardio-pulmonary bypass, in a setting of hypoxia-reoxygenation model to demonstrate the 
effect of known pharmacological inhibitors on MPTP opening at the time of reperfusion. We 
used the human cardiomyocyte model to demonstrate that inhibiting the opening of MPTP at 
reperfusion can be cardio-protective and increase the percentage of cellular viability and 
decrease the percentage of apoptotic and necrotic cells.   
 
6.3 Aim  
 
To determine whether pharmacologically inhibiting MPTP opening at the onset of 
myocardial reoxygenation improves the survival of human atrial cardiomyocytes (also 
decreasing the necrosis and apoptosis) subjected to a period of sustained simulated 
ischemia.  
 
6.3.1 Materials 
 
1) Cyclosporin-A: (Sigma Chemicals, Poole, Dorset) were dissolved in 50% ethanol and 
added to the enzyme solution such that the final ethanol concentration was less than 
0.005%. All other reagents were of standard analytical grade. 
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2) Sanglifehrin-A: (Novartis Pharma AG, Basel) was dissolved in dimethyl sulphoxide 
(DMSO, Sigma Chemicals, Poole, Dorset) and added to the modified Tyrode’s buffer 
such that the final DMSO concentration was less than 0.01%. All other reagents were 
of standard analytical grade. 
3) Medium / Low-calcium (MC) solution: comprising (in mM): NaCl 120, KCl 5.4, MgSO4 
5, pyruvate 5, glucose 20, taurine 20, HEPES 10 and Ca
2+
 1-2 M (pH 7.4). 
4) Enzyme Solution (mM): pH 7.4, Sodium Chloride (NaCl) 120, Potassium Chloride 
(KCl) 5.4, Magnesium Sulphate (MgSO4) 5, Pyruvate 5, Glucose 20, Taurine 20, 
HEPES 10, Calcium Chloride (CaCl2) 35 M.  
5) Modified Esumi Buffer (mM): pH 6.5, Sodium Chloride (NaCl), 137, Potassium 
Chloride (KCl), 12, Magnesium Chloride (MgCl2) 0.49, Calcium Chloride (CaCl2) 0.9, 
HEPES 4, Lactate 20 
6) Sodium Dithionite – 0.5 mM  
 
6.3.2 Isolated Human right Atrial Cardiomyocyte model 
 
The human right atrial samples were taken from patients undergoing bypass operations and 
the cardiomyocytes isolated from them were placed on 6 well plates and subjected to 20 
minutes of simulated ischemia (hypoxia) followed by 30 minutes of reperfusion 
(reoxygenation) (section 3.4 and 3.5). At the end of the reperfusion period, the percentages of 
viable cells, apoptotic cells and necrotic cells were determined using fluorescent microscope 
(section 3.5). 
 
6.3.2a Method of subjecting human atrial cardiomyocyte using hypoxic chamber for 
assessment of viability and percentage necrosis and apoptois under fluorescent 
microscope 
 
After stabilising the human atrial cardiomyocytes in the enzyme solution for 50-60 minutes in 
the incubation chamber the cells were transferred to the six well plates for the experiments. 
The cell suspension in the enzyme solution was divided into 2 ml solutions into eppendorffs 
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[2ml each – (1) for the control, (2) for hypoxia and reperfusion alone, (3) for hypoxia and CsA 
+ reperfusion and (4) for hypoxia and SfA + reperfusion]. These cells were centrifuged at 
1000 rpm for 1-2 minutes and re-suspended in the appropriate solutions i.e.  
1) The control group: cells was re-suspended back in the enzyme solution into a well of 
the six well plates and transferred back to the incubator to be kept at 37C.  
2) Hypoxic group: the cells subjected for hypoxic protocols were re-suspended in the 
modified Esumi Buffer and transferred into the wells of the six well plates. This group 
consists of both the hypoxic group and the drug groups (CsA and SfA) as all of them 
were subjected for hypoxic protocol. 
The cardiomyocytes in the plates were subjected to respective protocol as above - i.e. the 
control was re-suspended back into the enzyme solution in a well of the plates and put back 
in the incubator, and the cells subjected for hypoxic protocols were re-suspended into the 
modified Esumi Buffer and transferred into the wells of the six well plates. The plates for 
hypoxic protocol were transferred to the hypoxic chamber along with 0.5 mM of sodium 
dithionite (separately). The hypoxic chamber was closed airtight and the temperature was 
maintained at 37C. The air in the hypoxic chamber was sucked out using tubing connected 
to the cold-water tap (one way) for the first 5 minutes to produce vacuum. For the next fifteen 
(15 minutes) minutes the hypoxic chamber was flushed with argon gas (BOC) to replace any 
oxygenated air left in the chamber and to maintain hypoxia (combined 20 minutes of hypoxia). 
The outlet for the argon gas from the hypoxic chamber was connected to an underwater seal 
to prevent air entering into the hypoxic chamber.   
The ischemia / hypoxia was simulated by combination of (1) Modified Esumi Buffer, (2) 
Sodium Dithionate and (3) Hypoxia in the chamber. During this hypoxic period the control 
cells were counted for their baseline viability count under light microscope and the result is 
taken from the average of five fields from the single well by an independent observer.  
At the end of the twenty minutes of simulated ischemia the hypoxic chamber was opened 
and the drugs Cyclosporin-A (CsA) and sanglefehrin (SfA) were added to the cells 
respectively that are subjected for the drug protocol. Now the cells were pippetted out into 
separate eppendorffs including the control and are centrifuged for 1-2 minutes at 1000 rpm. 
The cells from all the groups were re-suspended into the enzyme solution (The cells in the 
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drug groups will get the drug CsA and SfA along with the enzyme solution) in separate wells 
of the 6 well plates, which were in turn incubated at 37C.  
During the reperfusion period cardiomyocytes were subjected to Annexin-V (A-V) and 
Propidium Iodide (PI) and were worked under darkness to prevent photosensitisation as 
follows
265,266
. At the end of 20 minutes of reperfusion, 200ul of Annexin-V (A-V) was added to 
the cardiomyocytes in the wells and reincubated. Similarly at the end of 30 minutes of 
reperfusion 1ml of Propidium Iodide (PI) was added to the myocytes just before the 
cardiomyocytes were subjected for counting under fluorescent microscope. The percentages 
of viable cells, necrotic cells and apoptotic cells were counted under the fluorescent 
microscope at the end of 30 minutes of the reperfusion period. The percentages of viable 
cells, necrotic cells and apoptotic cells were taken as the average count of three fields from 
each well by an independent person.  
 
The cells were accounted as follow (Figure 6.1):  
 Live cells  = rod shaped cells and no yellow stained nucleus. 
 Necrotic cells  = cells with yellow stained nucleus.  
 Apoptotic cells  = round cells and no yellow stained nucleus. 
 
 
Figure 6.1 Eample of picture showing Cardiomyocytes under fluorescent 
microscope after staining with Annexin-V and Propidium Iodide. A – 
Live cells (rod shaped); B – Necrotic cells (round cells with yellow stained 
nucleus) and C – Apoptotic cells (round cells with no stained nucleus). 
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6.3.3 Experimental Protocols 
 
The experiment protocols for the cellular viability of the atrial cardiomyocyte studies are 
presented in Figure 6.1. The cells were assigned to one of the following treatment groups:  
 
(1) Control Group: cardiomyocytes (n=6) were stabilised in the enzyme solution during 
the entire experiment of 70 minutes (equivalent of 20 minutes of simulated hypoxia 
and thirty minutes of reperfusion) This group was used as a positive (positive) control 
for the further experiments. 
(2) Hypoxic Group: cardiomyocytes (n=6) were subjected to simulated ischemia for 20 
minutes in the hypoxic chamber in the modified Esumi buffer along with sodium 
dithionate at 37C followed by 30 minutes of reperfusion in the enzyme solution in the 
incubator.  
(3) CsA-treatment: cardiomyocytes (n=6) were subjected to simulated ischemia for 20 
minutes followed by reperfusion with cyclosporin-A (0.2 mol/l) in the enzyme solution 
during the entire period of reperfusion (30 minutes).  
(4) SfA-treatment: cardiomyocytes (n=6) were subjected to simulated ischemia for 20 
minutes followed by reperfusion with sanglifehrin-A (1.0 mol/l) in the enzyme 
solution during the entire period of reperfusion (30 minutes).  
(5) DMSO Group: cardiomyocytes (n=3) were subjected to simulated ischemia for 20 
minutes followed by reperfusion with DMSO in the enzyme solution during the entire 
experiment of reperfusion (30 minutes). This group was used as a positive control for 
the drug group SfA. 
(6) 50% Ethanol Group: cardiomyocytes (n=3) were subjected to simulated ischemia for 
20 minutes followed by reperfusion with 50% ethanol in the enzyme solution during 
the entire period of reperfusion (30 minutes). This group was also used as a positive 
control for the drug group CsA. 
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Figure 6.2: Experimental Protocols for Investigating the Effect of CsA and SfA 
Inhibiting MPTP Opening on Viability of Human Right Atrial 
Cardiomyocytes. CsA – Cyclosporin A; SfA – Sanglifehrin A; DMSO - 
dimethyl sulphoxide. (Time control includes solvent group). 
 
 
 
 
 
6.4 Results  
6.4.1 Exclusions 
Samples were obtained from 36 patients with stable heart disease (27 men and 9 women; 
age range 51-78; mean age 67 years). When there were good yield of cells, it was able to 
allocate the cells for the above four-six groups of experiments. 14 samples were excluded 
because of poor / no cells in the digest or dead cells (no live cells) at the beginning of the 
experiment.  
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6.4.2 Experimental Data and results 
The baseline percentage of viable cells from the time control ranged from 22% to 39% and 
the average was 29%. The percentage of viable cells in the groups: CsA (15.8±0.7) and SfA 
(15.0±1.1) were significantly higher (P<0.001) compared to the hypoxic control (10.8±0.9) as 
well as their vehicle controls i.e. DMSO (9.3±0.9) and 50% Ethanol (9.0±1.2), (Figure 5.2a). 
The percentage of viable cells in the time control (16.3±1.2) was also significantly higher than 
the hypoxic and vehicle control groups (Figure 5.2a).  
 The percentage of necrotic cells in the drug groups CsA (48.5±1.6) and SfA 
(47.6±1.2) were significantly lower (P<0.04) than the hypoxic group (54.8±1.0) and also 
significantly lower than their vehicle control groups i.e. DMSO (54.0±0.6) and 50% Ethanol 
(56.3±1.2), (Figure 5.2c). 
Interestingly our experiment failed to show any statistical significant difference in the 
percentage of apoptotic cells among all the groups (Figure 5.2b). 
 
Groups Number % Live cells 
 
% Apoptotic cells 
 
% Necrotic cells 
 
1. Time Control 
6 16.3±1.2
#
 37.3±3.4 46.5±4.0 
 
2. Hypoxic control 
6 10.8±0.9 34.2±1.0 54.8±1.0 
 
3. CsA 
6 15.8±0.7* 36.2±1.6 48.5±1.6* 
 
4. SfA 
6 15.0±1.1* 37.5±1.8 47.7±1.2* 
 
5. DMSO 
3 9.3±0.9 37.0±0.6 54.0±0.6 
 
6. 50% Ethanol 
3 9.0±1.2** 34.7±0.33 56.3±1.2** 
Values are mean ± SEM.  
 
 
Table 6.1:  This table shows the percentage of Viable, Apoptotic and Necrotic cells 
at 30 minutes of reperfusion period.  CsA – Cyclosporin A; SfA – 
Sanglifehrin A; DMSO - dimethyl sulphoxide. 
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Figure 6.3.a:  This graph shows the % of live cells (cardiomyocytes) at 30 minutes of 
reperfusion. The % of live cells in the CsA and SfA groups were statistically 
higher than their hypoxic control counterpart, *P<0.001; as well as their 
vehicle groups, **P<0.001; whereas the % of live cells in the time control 
were statistically higher compared to the hypoxic and vehicle groups, 
#P<0.0002. CsA – Cyclosporin A; SfA - Sanglifehrin A; DMSO - dimethyl 
sulphoxide. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3.b:  This graph shows the % of apoptotic cells at 30 minutes of reperfusion. 
The % of apoptotic cells in all the groups were not statistically significant 
compared to each other, though there appears to be less apoptotic cells in 
the hypoxic and ethanol groups. CsA – Cyclosporin A; SfA - Sanglifehrin A; 
DMSO - dimethyl sulphoxide. 
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Figure 6.3.c:  This graph shows the % of necrotic cells at 30 minutes of reperfusion. 
The % of necrotic cells in the CsA and SfA groups were statistically lower 
than their hypoxic control counterpart as well as the ethanol vehicle group, 
*P<0.04; The % of necrotic cells in the 50% ethanol vehicle group were 
statistically higher than their time control counterpart, **P<0.01. CsA – 
Cyclosporin A; SfA - Sanglifehrin A; DMSO - dimethyl sulphoxide. 
 
  
 
6.5 Discussion 
In this part of the study we demonstrated that pharmacologically inhibiting MPTP opening for 
the first 30 minutes of reperfusion, following a lethal period of ischemia, using either 
cyclosporin-A (CsA) or sanglifehrin-A (SfA), protected the heart against lethal reperfusion 
injury, as evidenced by an increase in the recovery of the percentage live cells and a 
decrease in the percentage of necrotic cells. Importantly, the known MPTP inhibitors were 
only given at the time of reperfusion, to target the time period when MPTP opening has been 
demonstrated to occur
12,143,166,170
. Our experiments have shown that the opening of MPTP 
occurs during reperfusion and that by inhibiting its opening we could prevent the lethal effects 
of reperfusion injury and hence the MPTP is a target for cardioprotection in the human heart.   
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 The improvement in the percentage of live cells and decrease in the percentage of 
necrotic cells, induced by CsA at reperfusion was not due to its effect on calcineurin but was 
most likely due to its suppression of MPTP opening. In support of this, we also demonstrated 
protection against lethal reperfusion injury using sanglifehrin-A, which does not inhibit 
calcineurin
139,143
. Studies have demonstrated that the pharmacological inhibition of the 
apoptotic signalling cascade during the reperfusion phase is able to attenuate both the 
apoptotic and necrotic components of cell death
53,219,277
. Our study was able to show 
attenuation of the necrotic component of the human cardiac cardiomyocytes.  
The apoptotic component of cell death is believed to contribute to the extension of 
myocardial infarct size during reperfusion. Zhao and colleagues, demonstrated that 
pharmacologically inhibiting the reperfusion-induced apoptotic component of cell death 
resulted in improved contractile function of ischemic canine hearts
53
. Inhibiting MMP using 
MPTP inhibitors such as cyclosporine-A or bongkrekic acid have been demonstrated to inhibit 
apoptotic cell death
223,274,275
, suggesting that MPTP opening is an obligatory mediator of 
apoptosis. However, recent data in CyP-D deficient mice suggests that the CypD-regulated 
MPTP may not be crucial for apoptotic cell death which may explain why we failed to see an 
effect on the apoptotic component of cell death
195,278
. Although in the chapter four we 
managed to show statistical significance in the recovery of percentage contractile force of the 
human atrial trabeculae and show statistically significant improvement in the percentage of 
live cells (in chapter 5 and 6), our study did not show any statistically significant difference in 
the percentage of apoptotic cells among all the groups. Yet there seems to be a slightly 
increased percentage of apoptotic cells in the drug group (Figure 5.2b).  
 Therefore, providing these agents were administered in a timely manner, we were 
able to inhibit MPTP opening despite the presence of the MPTP-inducing factors that prevail 
during reperfusion. 
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6.6 Conclusion 
 
In conclusion, we have demonstrated that pharmacologically inhibiting MPTP opening during 
reperfusion protects the heart against lethal reperfusion injury as evident by increase in the 
percentage of viable cells and decrease in percentage of necrotic cells. From the results of 
this part of the study, it appears that the opening of the MPTP at the time of reperfusion 
mediates lethal reperfusion injury. The early period of reperfusion therefore represent a 
‘window of opportunity’ for interventions directed to attenuating lethal reperfusion injury, via 
inhibition of MPTP opening.  
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THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE: 
 
 A POTENTIAL TARGET FOR PROTECTING HUMAN MYOCARDIUM 
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7.1 Introduction 
 
Next we go on to show that MPTP opening occurs in human cardiomyocytes and also the 
direct effect, of inhibiting the mitochondrial permeability transition pore using the known 
inhibitors, Cyclosporin-A (CsA) and sanglifehrin-A (SfA), against injury induced by oxidative 
stress. We aimed to quantify the time delay in opening of the MPTP induced by oxidative 
stress.  
Opening of the MPTP in the first few minutes of reperfusion, following an episode of 
lethal ischemia is a critical determinant of cell death in ischemia-reperfusion. Opening of the 
MPTP results in both apoptotic and necrotic cell death, and the inhibition of its (MPTP) 
opening during ischemia-reperfusion injury has been demonstrated to confer protection in 
various experimental models
68,139,143,229,233,234
. Although cyclosporin-A (CsA) is a potent 
inhibitor of MPTP opening, it also has other actions, which include inhibiting the activity of the 
protein phosphatase, calcineurin. The novel immunosuppressant, sanglifehrin-A (SfA), has 
been shown, to also act as a potent inhibitor of MPTP opening. This drug has been 
demonstrated to be a more potent inhibitor of MPTP opening than CsA, and in addition SfA 
does not inhibit calcineurin
68,139,143,229,233,234
. All these studies were carried out in various 
animal and cellular models. Opening of the MPTP in adult rat myocytes was induced and 
detected using a well-characterised cellular model of oxidative stress
201,267-270
.  
However, to our knowledge there has been no study so far have examined the direct 
effect of inhibiting MPTP opening using known MPTP inhibitors CsA and SfA at the time of 
oxidative stress induced MPTP opening in human cardiomyocyte model. Therefore the aim of 
this study was to determine whether pharmacologically inhibiting MPTP opening can protect 
the human heart against lethal oxidative stress induced MPTP opening, using the percentage 
time delay of the opening of the MPTP as the measured end-point.  
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7.2 Hypothesis  
   
Opening of the MPTP at the time of reoxygenation / reperfusion is a critical determinant of cell 
death and inhibiting its opening is target for cardioprotection in the human heart. 
 
In this study we set out to demonstrate that MPTP opening does occur in human 
cardiomyocyte and also examine the role of the MPTP in mediating the cell death induced by 
lethal injury of oxidative stress in human cardiomyocyte model. We used cyclosporin-A and 
sanglifehrin-A to inhibit the MPTP opening that has been demonstrated to occur in the first 
few minutes of reoxygenation / reperfusion. We administered these agents at the time of 
opening of MPTP which is shown to occur at the time of reoxygenation / reperfusion in order 
to demonstrate that the opening of the MPTP is an important mediator of lethal reperfusion 
injury. We used samples from the right atrium of humans undergoing cardio-pulmonary 
bypass to demonstrate the effect of known pharmacological inhibitors on MPTP opening at 
the time of its opening. We used the human cardiomyocyte model to demonstrate the opening 
of MPTP and that inhibiting / delaying the opening of MPTP can be cardio-protective.    
  
7.3 Aim  
 
To demonstrate that MPTP opening occurs in human atrial cardiomyocytes subjected to 
oxidative stress, and that MPTP opening can be inhibited by known pharmacological MPTP 
inhibitors. 
 
7.3.1 Materials 
 
1. Cyclosporin-A (Sigma Chemicals, Poole, Dorset) were dissolved in 50% ethanol and 
added to the enzyme solution such that the final ethanol concentration was less than 
0.005%.  
2. Sanglifehrin-A (Novartis Pharma AG, Basel) was dissolved in dimethyl sulphoxide 
(DMSO, Sigma Chemicals, Poole, Dorset) and added to the enzyme solution such 
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that the final DMSO concentration was less than 0.01%. All other reagents were of 
standard analytical grade.  
3. Low calcium medium (mM): pH 6.96, Sodium Chloride (NaCl) 120, Potassium 
Chloride (KCl) 5.4, Magnesium Sulphate (MgSO4) 5, Pyruvate 5, Glucose 20, 
Taurine 20, HEPES 10, NTA 5, calcium 1-2 µM. 
4. Enzyme Solution (mM): pH 7.4, Sodium Chloride (NaCl) 120, Potassium Chloride 
(KCl) 5.4, Magnesium Sulphate (MgSO4) 5, Pyruvate 5, Glucose 20, Taurine 20, 
HEPES 10, Calcium Chloride (CaCl2) 35 µM. 
 
7.3.2 Isolated Human right Atrial cardiomyocyte model of MPTP opening 
 
Adult human atrial cardiomyocytes were isolated from according to the method in described in 
section 3.4. Isolated cardiomyocytes were seeded onto 25-mm round cover slips according to 
the method in described in section 3.6. Seeded cardiomyocytes, in enzyme solution, were 
incubated with the fluorescent dye, TMRM (3 mol/l) for 15 minutes at 37C, and visualised 
using confocal fluorescence microscopy, as described in section 3.6.  
 TMRM which is a lipophilic cation selectively accumulates into mitochondria according 
to the mitochondrial membrane potentia
271
. Opening of the MPTP was induced and detected 
using a cellular model of oxidative stress. Laser-illumination, of this TMRM that has already 
accumulated within the mitochondria, photosensitises the TMRM, generating reactive oxygen 
species (ROS) from within the mitochondria
272
, which induce opening of the MPTP. Opening 
of the MPTP permeates the inner mitochondrial membrane resulting in uncoupling of 
oxidative phosphorylation. This leads to subsequent collapse of the mitochondrial membrane 
potential
267,279
. Oxidative stress generated on reperfusing ischemic myocardium also involves 
the excess production of ROS from within the mitochondria, and this model therefore 
simulates the events associated with lethal reperfusion injury. This model represents a widely 
reported and reliable way to reproducibly induce the loss of mitochondrial membrane 
potential, which has been unequivocally identified as MPTP opening
180,267,268,270,279
. 
The relatively high concentration of TMRM in the mitochondria causes auto-
quenching of fluorescence and the fluorescence signal becomes a non-linear function of dye 
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concentration. The mitochondrial membrane depolarisation results in the loss of dye into the 
cytosol where the signal increases
272
. Laser-induced oxidative stress was applied until MPTP 
opening had been induced (indicated by collapse of the mitochondrial potential) and the 
duration of time taken to induce MPTP opening was measured (corresponding to the ROS 
burden required to induce MPTP opening). 
  
7.3.3 Experimental Protocols 
 
After loading with TMRM in the enzyme solution, cells were randomly assigned to one of the 
following treatment groups. Cells in the drug groups were incubated for 15 minutes with the 
drug(s) at 37˚C and were then subjected to the TMRM-oxidative stress protocol. 
 
(1) Control Group: cardiomyocytes (n=11) were stabilised in the enzyme solution 
during the entire experiment. 
(2) CsA-treatment: cardiomyocytes (n=10) were perfused with cyclosporin-A (0.2 
mol/l) in the enzyme solution during the entire period of experiment along with 
TMRM.  
(3) SfA-treatment: cardiomyocytes (n=10) were perfused with sanglifehrin-A (1.0 
mol/l) in the enzyme solution during the entire period of experiment along with 
TMRM.  
(4) DMSO Group: cardiomyocytes (n=6) were perfused with DMSO in the enzyme 
solution during the entire experiment. This group was used as a positive control 
for the drug group SfA. 
(5) 50% Ethanol Group: cardiomyocytes (n=6) were perfused with 50% ethanol in 
the enzyme solution during the entire experiment. This group was also used as a 
positive control for the drug group CsA. 
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Figure 7.1: Experimental Protocols for Investigating the Effect of CsA and SfA on 
Direct Inhibition of MPTP Opening using oxidative stress model of 
TMRM. CsA – cyclosporin A; SfA – Sanglifehrin A; DMSO - dimethyl 
sulphoxide 
 
 
7.4 Results  
 
7.4.1 Exclusions 
Samples were obtained from 35 patients with stable heart disease (28 men and 7 women; 
age range 49-74; mean age 62 years). When there were good yield of cells, it was able to 
allocate the cells for the above four-six groups of experiments. 4 samples were excluded 
because of poor / no cells in the digest or dead cells (no live cells) at the beginning of the 
experiment. 
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7.4.2  Experimental Data and results 
 
The times taken to induce global mitochondrial membrane depolarisation were noted and in 
the control group, MPTP opening was routinely induced after (115.6±7.8) (see table 7.1) 
seconds of laser-induced oxidative stress (see figure 7.2). The times taken to induce global 
mitochondrial membrane depolarisation in the drug group CsA (189.1±10.2) and SfA 
(183.0±12.2) (see table 7.1) were significantly (P<0.0001) higher than the control group and 
their vehicle groups i.e. DMSO (109.8±8.4) and 50% Ethanol (99.8±5.2) (see table 7.1).  
This observed global mitochondrial membrane depolarisation induced by laser induced 
oxidative stress actually represents opening of the MPTP and this was demonstrated by 
showing that it was sensitive to cyclosporin-A (CsA), the most reliable inhibitor of MPTP 
opening
96
. CsA was shown to extend the time required to induce opening of the MPTP from 
115.6±7.8 seconds to 189.1±10.2 seconds (P<0.0001, figures 7.2). However, as well as 
inhibiting MPTP opening, CsA inhibits the phosphatase, calcineurin. 
To exclude the effect of CsA-induced inhibition of calcineurin, we tested with sanglifehrin-A
139
. 
SfA also significantly prolonged the time taken to induce both MPTP opening to 183.0±12.2 
(P<0.0001, figure 7.2). Furthermore, sanglifehrin-A was shown to be a similar potent inhibitor 
of MPTP opening as CsA in extending the time taken to induce MPTP opening. 
 
 
Groups 
 
Number Time (seconds) 
 
1. Control 
11 115.6±7.8 
 
2. CsA 
10 189.1±10.2* 
 
3. SfA 
10 183.0±12.2* 
 
4. DMSO 
6 109.8±8.4 
 
5. 50% Ethanol 
6 99.8±5.2 
 
Values are mean ± SEM.  
 
Table 7.1:  This table shows the time taken to induce MPTP opening (seconds) by 
laser induced oxidative stress.  CsA – Cyclosporin A; SfA – Sanglifehrin A; 
DMSO - dimethyl sulphoxide. 
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Figure 7.2:  This graph shows the time taken for MPTP opening indicated by the 
membrane depolarisation due to oxidative stress induced by TMRM. 
The time taken for MPTP opening of the cells in the CsA and SfA groups 
were statistically higher than their control counterpart (including groups 
DMSO and 50% Ethanol), *P<0.0001. CsA – Cyclosporin A; SfA - 
Sanglifehrin A; DMSO - dimethyl sulphoxide. 
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Figure 7.3: Confocal Images of TMRM-loaded Human Atrial Cardiomyocytes. 
Confocal fluorescent images are from time sequences in which two 
cardiomyocytes were subjected to laser-induced oxidative stress. They 
demonstrate the typical changes in mitochondrial membrane potential that 
occur in response to oxidative stress: (a) Beginning of oxidative stress. (b) 
Cardiomyocyte with partially depolarised membrane (localised areas devoid 
of TMRM fluorescence). (d) Cardiomyocyte with global mitochondrial 
depolarisation (as MPTP opening has taken place in most of the 
mitochondria).   
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7.5  Discussion   
 
This technique has been used in a number of different laboratories and represents a 
reproducible technique for inducing and detecting MPTP opening in the intact cell
148,267-
270,279,280
. We used an established model for both inducing and detecting MPTP opening in the 
intact human cardiomyocyte. Laser-illumination of TMRM generates oxidative stress from 
within mitochondria, inducing MPTP opening and is detected by global mitochondrial 
membrane depolarisation. Following the induction of MPTP opening continued oxidative 
stress results in ATP depletion.  
The laser-induced collapse in mitochondrial membrane potential (detected by 
increased TMRM fluorescence) was demonstrated to be sensitive to the potent MPTP 
inhibitor, cyclosporine-A (CsA)
125
. We also demonstrated that the observed mitochondrial 
membrane depolarisation was sensitive to sanglifehrin-A
68,229,233,234
. 
In the current model to investigate MPTP opening, oxidative stress by laser 
illumination was continued until global mitochondrial membrane depolarisation has occurred 
which in turn reflects the opening of the MPTP. Both the control and drug-treated cells were 
exposed to equal burdens of oxidative stress. One would expect neither CsA nor SfA to 
completely suppress global mitochondrial membrane depolarisation (MPTP opening) under 
these extreme conditions of oxidative stress. From the current data it is clear that CsA and 
SfA increases the tolerance of the human myocardial cells for global mitochondrial membrane 
depolarisation to oxidative stress compared to control, suggesting that both CsA and SfA are 
able to delay the global mitochondrial membrane depolarisation and in turn suggesting that 
MPTP opening can be inhibited at the time of reperfusion.  
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7.6  Conclusion 
 
 
In conclusion, we have demonstrated that MPTP opening does occur in human 
cardiomyocyte and pharmacologically inhibiting this MPTP opening protects the heart against 
lethal oxidative stress induced injury as evident by increase in the percentage of time duration 
for the opening of the MPTP. From the results of this part of the study, it appears that the 
opening of the MPTP mediates lethal injury. The early phase of reperfusion where MPTP 
opening is shown to occur, therefore represent a ‘window of opportunity’ for interventions 
directed to attenuating lethal reperfusion injury, via inhibition of MPTP opening.  
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Chapter Eight: 
 
 
 SUMMARY AND DISCUSSION 
 
 
 
Coronary artery disease and myocardial infarction are a major cause for increasing mortality 
and morbidity in our population. To improve our current treatments novel therapeutic 
approaches are urgently required. Primary prevention strategies such as lifestyle changes, 
diet, exercise, anti-platelet agents, statins, ACE-inhibitors, HMG-CoA reductase inhibitors and 
secondary prevention strategies like anti-platelet agents, thrombolytic agents, primary PTCA, 
drug-eluting stents and surgery have made a significant impact.  
 The powerful phenomenon of ischemic preconditioning was studied and described by 
Murry et al in 1986
3
. This phenomenon of myocardial preconditioning has been well 
established and experiments have shown that it can deliver a powerful protection towards the 
heart against the lethal ischemia-reperfusion injury. In practice, preconditioning means 
intervening before the index ischemic episode of the acute coronary syndrome. This is difficult 
practically. Nevertheless preconditioning can be applied as an adjuvant to patients during 
acute coronary syndrome and to patients undergoing cardiac surgery. 
 Hence a practical cardio-protective strategy is to intervene after the index ischemic 
event. Currently adjuncts to reperfusion treatment strategies such as thrombolysis, primary 
PTCA and cardiac intervention offers a powerful protective approach.   
 To salvage the myocardium that is viable following ischemia, reperfusion process is 
essential and this reperfusion is paradoxically associated with cardiomyocyte death that was 
viable at the beginning of reperfusion
281
. This phenomenon is described as ‘lethal myocardial 
reperfusion injury’, and this clearly compromises the complete benefit of myocardial 
reperfusion
2,55
. Currently we do not have an effective therapeutic strategy to protect the 
myocardium against this lethal reperfusion injury. Therefore, novel strategies are urgently 
needed that are able to protect the myocardium against this lethal reperfusion injury and can 
be administered as an adjunct at the time of reperfusion to reduce the myocardial injury which 
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in turn will preserve and improve the myocardial function and the outcome of the of patients.  
The mitochondrial permeability transition pore (MPTP) has emerged as one of the important 
target for cardioprotection
68,177,282
. Opening of MPTP at the beginning of reperfusion of the 
myocardium following ischemia in the setting of acute ischemia–reperfusion / hypoxia-
reoxygenation injury is an important and major determinant of cardiac dysfunction and cell 
death and hence opening of MPTP presents a potential target for human cardio-protection. 
 This thesis examined the importance of the MPTP as a potential target for human 
myocardial protection against the lethal hypoxia-reperfusion / ischemic-reperfusion injury. We 
found that opening of MPTP does occur in human cardiomyocytes. We have also identified 
that inhibiting this MPTP opening which takes place at reoxygenation / reperfusion is a 
potential target for cardio-protection when the protection was mediated by interventions that 
were applied solely at the time of reoxygenation / reperfusion. 
 The main findings of this thesis were: The MPTP is a critical determinant of 
myocardial death in the setting of hypoxia-reperfusion / ischemia-reperfusion injury, and 
pharmacologically inhibiting its opening, solely at the time of reoxygenation / reperfusion, 
protects the human heart against lethal reperfusion injury, as evidenced by; 
 
1. Improving the functional recovery of the human right atrial trabeculae 
2. Improving the human myocardial cellular viability  
3. Decreasing the human myocardial cellular necrosis 
4. Demonstrating that MPTP opening occurs in human cardiomyocyte and  
5. Delaying the timing of the opening of the MPTP 
 
 
The MPTP as a Mediator of Lethal Reperfusion Injury 
 
In chapter 4, we demonstrated, using the isolated perfused human atrial trabeculae model, 
that the presence of the known pharmacological MPTP inhibitors, cyclosporin-A or 
sanglifehrin-A at the beginning of reoxygenation / reperfusion, protected the heart against 
lethal reperfusion injury, as evidenced by a significant increase in the recovery of the baseline 
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contracture following a lethal ischemic insult in the setting of hypoxia- reoxygenation. 
Importantly, we demonstrated that targeting reoxygenation / reperfusion was critical to the 
protective effect of these MPTP inhibitors, which supports the experimental findings that the 
MPTP opening occurs during post-ischemic reperfusion. The atrial trabeculae model has 
been well established and standardised and shown to work in our laboratory
260-262
. There are 
both advantages and disadvantages in using the right atrial muscle preparations as outlined 
in chapter 3. In vitro evidence from Ikonomidis et al was one of the early studies to show that 
ventricular cadomyocytes could be protected from SI by preconditioning
19
. Extensive studies 
at our department has shown that human atrial trabeculae can be preconditioned and this can 
be translated to better recovery of the contractile function following hypoxia and 
reoxygenation
18
. Though we are aware of the possible existence in the differences between 
atrial and ventricular cardiomyocytes, the human atrial model has been well established in our 
institution with reproducible results and hence this well established model was used in my 
experiments. Also our unpublished data from 1995 suggests that identical preconditioning 
effect can be induced in the ventricular tissue with a shorter hypoxic insult. The lack of tissue 
availability from ventricle is a limitation for conducting such experiments. Improvement in 
recovery of contractile function and reduction in infarct size secondary to preconditioning was 
shown by Jenkins et al and they showed that reduction in infarct size was proportional to 
improvement in the global left ventricular recovery
252
. In our experiment we assumed the 
same even though the experiment was performed in the human atrial tissue and there is no 
direct evidence. In addition the clinical studies support that the preconditioning does occur in 
humans
28,34,36,245-247
. 
 A period of hypoxic superfusion and rapid pacing to stimulate ischemia has been 
shown to induce preconditioning in both animal models of regional and global hypoxia and in 
cell cultures
248-251
. The combination of hypoxia and rapid pacing in the human atrial 
trabeculae has been studied extensively and reproducibly in our institution and 
preconditioning has been shown to improve their functional recovery
260-262
. The hypoxic 
preconditioning protocol has also been previously demonstrated in this atrial trabeculae 
model to improve the recovery of myocardial contractile function
18
.   
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 Pharmacological Inhibition of the opening of MPTP by the immunosuppressive agent, 
CsA was discovered in the late 1980s
125
. In 1993, Griffiths and Halestrap first reported the 
CsA protection against the sustained myocardial ischemia reperfusion injury. They showed 
that the protection of CsA at a dose of 200 nM improved functional recovery in the isolated 
perfused rat heart model but not at 1 nM. CsA treatment also showed preservation of the 
myocardial ATP content in the above setting following acute ischemia reperfusion injury
130
. 
They also demonstrated that calcineurin was not responsible for the cardioprotection by 
adding tacrolimus, known calcineurin inhibitor, to their experiments and failed to show the 
myocardial protection against acute IRI in the presence of tacrolimus
130
. Following this in 
1995 they investigated the timing of the opening of MPTP in relation to ischemia and 
reperfusion using a novel model of Hot-DOG technique
143
. They were able to show that the 
opening of the MPTP occurred in the first couple of minutes of myocardial reperfusion and 
that the MPTP remained closed during ischemia
143
. Opening of MPTP in the first few minutes 
of reperfusion was confirmed by a number of other studies subsequently
147,203
. Myocardial 
protection was shown by specifically inhibiting the opening of the MPTP at the time of 
reperfusion
203,229
.  
 Our laboratory in 2002 were the first to demonstrate the protective effect of CsA against 
the myocardial infarct size in the isolated perfused rat hearts in that CsA was administered 
solely at the onset of myocardial reperfusion only to confirm that the opening of MPTP 
occurred primarily at the onset of myocardial reperfusion
229
. In addition, Sanglifehrin A was 
shown to be cardioprotective against ischemia reperfusion injury by administering them at the 
onset of myocardial reperfusion
68
. Sanglifehrin A inhibits mitochondrial CyP and it does not 
affect calcineurin activity and it was demonstrated that when SfA was administered after the 
first 15 minutes of myocardial reperfusion following ischemia cardioprotection was lost 
completely. This underpins the importance of the timing of opening of MPTP and their 
intervention during the first few minutes of myocardial reperfusion
68. 
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 The understanding of the concept and timing of the opening of MPTP as an important 
mediator of myocardial reperfusion injury gives us an opportunity to intervene and inhibit the 
opening of MPTP and in turn protect the myocardium against ischemia reperfusion injury. 
In 2008, Piot et al showed that a single bolus of CsA was cardioprotective in patients 
presenting with an acute myocardial infarction. In this study CsA was given at the time of 
percutaneous coronary intervention to the patients presenting with acute MI and they have a 
reduction in the myocardial infarct size by 30-40%
135
. 58 patients who were presenting with 
acute ST- elevation MI were randomly assigned to two groups. They either received normal 
saline or CsA bolus intravenously just before percutaneous intervention and they showed that 
the group receiving CsA bolus had smaller infarct size and a significant reduction in the 
release of Creatine Kinase (P=0.04)
135
. Interestingly further studies in porcine model have 
shown mixed results
136,284
 and the reason for this mixed finding is not clearly evident. 
 Here we used this well-known MPTP inhibitor CsA, solely at the time of reperfusion / 
reoxygenation. As CsA can inhibit the protein phosphatase calcineurin in addition to inhibiting 
the opening of MPTP, we used SfA to show that MPTP inhibition is possible without 
calcineurin inhibiton
139
 and this has been shown in langerdorff perfused heart model
139-142
. 
The specified concentrations of CsA and SfA have been demonstrated to inhibit the opening 
of MPTP in the isolated perfused rat heart model
68,130,139,229
. We used the same concentration 
as it was used in our laboratory for the inhibition of MPTP at the time of reoxygenation / 
reperfusion in the animal models as it was shown to be effective in preventing the opening of 
MPTP. The following clinical studies are supportive of our finding of CsA inhibition of MPTP at 
the time of reoxygenation. CsA protection against ischemia reperfusion injury has been 
concurred in other settings like neonatal cardioplegic arrest
137,285
 and resuscitated cardiac 
arrest
138
. Leung and co-workers
137
 demonstrated that CsA sensitive MPTP opening occurs at 
the time of reperfusion in a neonatal rabbit cardioplegic arrest model and that inhibition of this 
opening of MPTP using CsA or other MPTP inhibitors would be useful in reducing reperfusion 
injury during peri-operative period. Cour and colleagues
137
 administered CsA in rabbits 
subjected to primary asphyxial cardiac arrest. Intravenous administration of CsA at the time of 
reperfusion has shown to improve survival and reduce myocardial necrosis. They also 
demonstrated inhibition of MPTP opening in isolated cardiac mitochondria by CsA.  
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The findings from this part of the study suggested that the MPTP opening during 
reoxygenation / reperfusion can determine cell death, and that inhibiting its opening provide a 
potential target of cardio-protection and improve its functional recovery. 
In chapter 5 and 6, we demonstrated, using the human atrial cardiomyocyte model, 
that the presence of the known MPTP inhibitors, cyclosporin-A or sanglifehrin-A during the 
onset of reoxygenation / reperfusion, protected the heart against reperfusion injury, as 
evidenced by a significant increase in the recovery of the viable cells and a reduction in the 
necrotic cells following a lethal ischemic insult in the setting of hypoxia-reoxygenation. 
Isolated adult human right atrial cardiomyocytes provide cells, which are free from the neuro-
hormonal influence in an environment, which can be controlled. MPTP opening results in both 
apoptotic and necrotic cell death
12,166,202,209,214
 and the inhibition of its opening during 
reperfusion has been demonstrated to confer cardioprotection in various experimental 
models. In myocytes subjected to lethal hypoxia-reoxygenation, the presence of CsA 
improved cell viability
127
. Studies have demonstrated that both apoptotic and necrotic 
components of cell death can be reduced by inhibiting the apoptotic signalling cascade during 
reperfusion using pharmacological inhibitors
53,219,277
. Inhibiting MMP using MPTP inhibitors 
such as cyclosporine-A or bongkrekic acid have been demonstrated to inhibit apoptotic cell 
death
222,223,274,275
 suggesting that MPTP opening is an obligatory mediator of apoptosis. Our 
study was able to show attenuation of the necrotic component of the human cardiac 
cardiomyocytes but failed to show any attenuation of the apoptotic component. Apoptosis can 
contribute to the extension of cell death and infarct size during reperfusion. Zhao and 
colleagues, demonstrated an improvement in the contractile function of canine hearts 
subjected to ischemia by inhibiting the reperfusion induced apoptotic component of cell 
death
53
. Although we could not demonstrate any significant reduction in the apoptotic 
component in the human atrial cardiomyocyte model, on the contrary we were able to 
demonstrate an improved contractile function of the human atrial trabeculae in the functional 
recovery model. This raises the question of whether apoptosis contributes to the functional 
recovery in our experiments. In our experiment the failure to shown any reduction in the 
apoptotic component of the myocytes could be explained by the fact that the hypoxic insult 
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could be severe and significant enough to cause necrosis on the fragile human cardiac 
myocytes and one suggestion would be do reduce the timing of the hypoxic insult.  
Human right atrial cardiomyocytes were isolated from the right atrial appendages 
harvested from the patients undergoing elective cardiac surgery, just before going on to 
cardio-pulmonary bypass
263 by enzymatic dissociation using protease and collagenase 
digestion. We used the myocyte extraction method as used by Harding et al
263
. Though they 
used the protocol to extract myocytes from the ventricle, we utilised the same method to 
extract the right atrial cardiac myocytes and we were successful in isolating and carrying 
experiments on the right atrial cardiac myocytes.   
Here again we used the same concentration of CsA and SfA in our mycocyte 
experiments, which is shown to potentially inhibit the MPTP opening at the time of 
reperfusion
68,229
. In chapter 5 first we attempted to characterise the model of ischemia / 
reperfusion in the human cardiomyocytes using hypoxic chamber to induce simulated 
ischemia / hypoxia simultaneously. Three time points (10, 30 and 50 minutes) were chosen to 
assess the cellular viability during the reoxygenation period following hypoxia. The 30-minute 
reoxygenation period was chosen as the time point for assessing cellular viability for further 
experiments of hypoxia and reoxygenation in chapter 6. Though we are aware that opening of 
MPTP occurs during the first few minutes of reoxygenation / reperfusion, we wanted to 
assess the cardiac cellular viability at three different time points as mentioned before (10, 30 
and 50 minutes) using the well known MPTP inhibitors CsA and SfA. 
 In chapter 7, we demonstrated, using the human atrial cardiomyocyte model, that the 
opening of MPTP (global mitochondrial membrane depolarisation) does occur and that the 
presence of the known pharmacological MPTP inhibitors, cyclosporin-A or sanglifehrin-A 
protected the heart against lethal reperfusion injury, as evidenced by a significant increase in 
the time delay in opening MPTP (global mitochondrial membrane depolarisation), following 
laser induction (oxidative stress). MPTP opening in adult rat myocytes was detected using a 
cellular model of oxidative stress
68,139,143,229,233,234
. This model represents a reliable way to 
reproducibly inducing the loss of mitochondrial membrane potential and this has been 
unequivocally identified as MPTP opening
180,267,268,270,279
.  The findings from this part of the 
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study suggested that the opening of the MPTP is a critical determinant of cell death and that 
inhibiting its opening provide a potential target of cardio-protection. 
  
The MPTP and Cardio-Protection in Myocardial Preconditioning 
We were also able to demonstrate that ischemic preconditioning of the human atrial 
trabeculae could protect the human myocardium from lethal reperfusion injury as evidenced 
by the functional recovery of the atrial trabeculae in the setting of ischemia reperfusion 
(chapter 4). Also in chapter 5 we were able to demonstrate a significant increase in the 
percentage recovery of viable human atrial cardiomyocytes subjected to hypoxic 
preconditioning followed by lethal ischemic insult in a setting of hypoxia-reoxygenation.   
Several studies have been published, confirming that inhibiting MPTP opening is 
critical to the protection associated with myocardial preconditioning
140,280
. Preconditioning 
may inhibit MPTP opening at the time of reperfusion by several possible mechanisms 
including an indirect effect, in which known inducing factors of MPTP opening, such as 
mitochondrial Ca
2+
 load,
147,286-290
 ATP depletion,
291,292
 and oxidative stress
293-295
 are 
counteracted by the effects of preconditioning, such that MPTP opening does not occur 
during the first few minutes of reperfusion. We did not investigate the association between 
IPC and MPTP in our study. 
Selvaraj Shanmuganathan Chapter 9: Conclusion  
 124 
 
Chapter Nine: 
CONCLUSION 
9.1 Summary of Findings 
 
This thesis has examined the role of the mitochondrial permeability transition pore (MPTP) in 
human myocardial protection and for the first time we have demonstrated the role of the 
MPTP as a viable target for myocardial protection with human cardiac muscle. We have 
demonstrated that the MPTP opening during reperfusion is a critical determinant of cell death 
in the setting of ischemia-reperfusion / hypoxia-reoxygenation injury, and therefore inhibiting 
its opening by administration of agents solely at the time of reperfusion, is an effective cardio-
protective strategy. We also demonstrated that MPTP opening does occur in human 
myocardium and can be inhibited by the MPTP inhibitors CsA and SfA. We demonstrated that 
the interventions applied solely at the time of reoxygenation / reperfusion protected the 
human myocardium by targeting MPTP and the effect was similar to myocardial 
preconditioning.  
 Simulated hypoxia-regeneration injury was used in two different models where human 
atrial tissues were subjected to hypoxia-reoxygenation and we have found cardioprotection by 
inhibiting the opening of MPTP at the time of reoxygenation. Also for the first time we have 
demonstrated the cardioprotective effects of the pharmacological inhibitors using a human 
cardiomyocyte model for inducing and detecting MPTP opening. We used CsA and SfA to 
inhibit MPTP opening in our models. 
  We have used the human atrial trabecula model that has been well established in our 
laboratory
18,260-262,296
 and others
21,297
. This is a robust model and is reproducible for hypoxia-
reoxygenation injury. It has been shown before that the percentage recovery of the baseline 
contractile function is a measure of cardioprotection and this is very much reproducible. We 
were able to demonstrate the improvement in the recovery of the contractile function of the 
human atrial trabeculae function by inhibiting the opening of the MPTP using the known 
MPTP inhibitors for the first 30 minutes of the reoxygenation period. The functional recovery 
of the atrial trabeculae were similar to those subjected to hypoxic preconditioning and this 
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implies that MPTP opening is a critical determinant of reoxygenation injury and cell death in 
human myocardium. 
 We used a cardiomyocyte model for our next part of the study, isolated from the human 
right atrium, and subjected them to hypoxia-reoxygenation injury and we looked at the cellular 
viability of those human cardiomyocyte in relation to MPTP opening and their inhibition. We 
found an improvement in the cellular viability by inhibiting the opening of MPTP at the time of 
reoxygenation. In our experiments it was interesting to see attenuation in the necrotic 
component of the cell death but not in the apoptotic component. Protection against both 
necrotic and apoptotic component of cell death has been shown before by inhibiting MPTP 
opening
298
. We were only able to demonstrate a reduction in necrosis using hypoxia-
reoxygenation injury in our human atrial cardiomyocyte model and we can attribute this to a 
limited reoxygenation time that was used in our experiment. We could speculate that there 
could have been an observed difference in the apoptotic component of cell death if we had 
extended the reoxygenation time period. Other explanation could be that MPTP opening is 
only involved in mediating necrosis but not apoptosis and this was supported by a recent 
study where over expression of Cyclophilin D promoted necrosis but appeared to inhibit 
apoptosis component of cell death
228
. 
 Though many different models of ischemia and reperfusion injuries have demonstrated 
the effect of MPTP opening as critical determinant of cell death, to our knowledge this is the 
first time we have demonstrated the role of MPTP in the human heart as a determinant of 
functional recovery and cellular viability. Schneider et al
299
 demonstrated the protective effect 
of CsA in the slices of human atrial tissues in regard to reoxygenation injury but they 
subjected the human atrium to CsA even before the hypoxic period and also MPTP was not 
investigated. In our study we aimed and administered the known MPTP inhibitors at the onset 
of reoxygenation period where the opening of MPTP occurred so that we could prevent their 
lethal effects of reoxygenation injury. We also demonstrated the direct protective effect of 
these drugs on MPTP using a human cardiomyocytes model. 
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 In this study, subjecting the human atrial tissues to hypoxia-reoxygenation injury we 
have demonstrated the protective effects of known MPTP inhibitors CsA and SfA. We used 
both of these inhibitors because CsA can be cardioprotective not only by inhibiting the 
opening of MPTP but also by inhibiting calcineurin and more importantly SfA is a more 
specific inhibitor of MPTP opening as it does not inhibit calcineurin
139,141
. We administered 
both these known MPTP inhibitors particularly at the onset of reoxygenation following a lethal 
period of ischemia so that we could target the opening of MPTP that has been observed and 
demonstrated to occur at the onset of reperfusion/reoxygenation
143,147,202,203
. Translating this 
to the clinical settings it would be easier to apply cardioprotective strategies at the time of 
reperfusion. 
 In conclusion, for the first time we have show that the human myocardium can be 
protected from lethal hypoxia-reoxygenation injury by inhibiting the MPTP opening at the time 
of reoxygenation. Inhibition of the opening of MPTP may therefore provide a novel target for 
cardioprotection in the clinical settings of reperfusion. 
 
9.2 Clinical Implications 
 
In this thesis, we have provided evidence that pharmacological intervention at the start of 
reperfusion / reoxygenation protects the human heart by inhibiting the MPTP opening which 
occurs during the first few minutes of reperfusion / reoxygenation. Therefore, the first few 
minutes of reperfusion / reoxygenation offer a potential target for cardio-protection which 
would be under the control of the operator, such as after an acute myocardial infarction or at 
the time of cardiac surgery (clinical settings of ischemia-reperfusion injury), and from the 
findings of this thesis, targeting the MPTP opening, can offer protection that is comparable to 
myocardial preconditioning.  
 Importantly, we demonstrated that the opening of the MPTP during reperfusion was a 
major determinant of lethal reperfusion injury and was responsible for a significant loss in the 
percentage of myocardial functional recovery and cellular viability and a significant increase in 
the percentage of human myocardial necrosis following an episode of lethal ischemia / 
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hypoxia. We demonstrated that inhibiting MPTP opening during reperfusion by administering 
known pharmacological MPTP inhibitors, the human myocardium could be protected.  
 Reliable pharmacological agents need to be developed that will specifically inhibit the 
MPTP opening, safe to use, rapid action and no adverse effects. They can be used at the 
time of reperfusion, in the clinical settings of ischemia-reperfusion injury, such as at the time 
of reperfusion (by either thrombolysis or primary PTCA) following an acute coronary 
syndrome, acute myocardial infarction and at the time of cardiac surgery. However, the drug 
would have to be administered as an adjunct to the reperfusion treatment strategy to be 
effective, as we have demonstrated in this thesis that targeting the post-ischemic reperfusion 
is critical to protection.  
 In 2008, Piot et al showed that a single bolus of CsA was cardioprotective in patients 
presenting with an acute myocardial infarction. In this study CsA was given at the time of 
percutaneous coronary intervention to the patients presenting with acute MI and they have a 
reduction in the myocardial infarct size by 30-40%. 58 patients who were presenting with 
acute ST- elevation MI were randomly assigned to two groups. They either received normal 
saline or CsA bolus intravenously just before percutaneous intervention and they showed that 
the group receiving CsA bolus had smaller infarct size and a significant reduction in the 
release of Creatine Kinase (P=0.04). The reduction in the infarct size by cyclosporin suggests 
that reperfusion injury occurs in humans
9,53
. The possibility of new pharmacological target for 
treating patients with ongoing coronary syndrome to reduce lethal reperfusion injury is 
evident
53,61
. Staat et al described a similar reduction in infarct size using ischemic post 
conditioning
61
. Post conditioning also reduces the extent of reperfusion injury by inhibiting the 
permeability-transition pore opening
229,244
. These data require confirmation in a larger clinical 
trial. However these studies are supportive of our study that MPTP opening does occur in the 
human myocardium and it is a potential target for preventing lethal ischemia-reperfusion injury 
by the application of known MPTP inhibitors largely at or just after the time of reoxygenation / 
reperfusion. 
Therefore, the local intra-coronary delivery of a small concentration of CsA or SfA, at 
the time of primary angioplasty for an AMI or following cardiac surgery, may provide a 
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potential approach for harnessing the protection gained from inhibiting MPTP opening at the 
time of reperfusion
300
.  
 
9.3 Future Directions 
 
Further experimental studies are required to investigate newer classes of drugs which inhibit 
MPTP opening and which can be demonstrated to offer protection against lethal reperfusion 
injury by inhibiting MPTP opening. Known inhibitors like CsA and SfA need to study further for 
their safety and efficacy to be used in human subjects. This will become an effective adjunct 
to the reperfusion strategy and hence salvage of human myocardium in an acute myocardial 
infarction setting. Also it will be interesting to see whether other interventions which have 
been demonstrated to protect the heart against lethal reperfusion injury, when applied solely 
at reperfusion, such as the phenomenon of ‘ischemic post-conditioning’ or the opening of the 
mitochondrial KATP channel, do so by inhibiting MPTP opening and could be used in 
combination with pharmacological MPTP inhibitors at the time of reperfusion.   
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